Effects of Charge and Hydrophobicity on the Oligomerization of Macrocyclic β-Sheet Peptides derived from Islet Amyloid Polypeptide

DISSERTATION

submitted in partial satisfaction of the requirements for the degree of

DOCTOR OF PHILOSOPHY

in Chemistry

by

Yilin Wang

Dissertation Committee:
Professor James Nowick, Chair
Associate Professor Jennifer Prescher
Professor David Van Vranken

2017
DEDICATION

To

my grandparents and parents

for supporting me,

even when it meant that I was not by their side.
# TABLE OF CONTENTS

LIST OF FIGURES v

LIST OF TABLES vii

ACKNOWLEDGMENTS viii

CURRICULUM VITAE ix

ABSTRACT OF THE DISSERTATION xiv

CHAPTER 1: Introduction 1

CHAPTER 2: Design of Macrocyclic $\beta$-Sheet Peptides Associated with Amyloid $\beta$ and Islet Amyloid Polypeptide 9

## Introduction

- Characterization of peptide 1b 27
- Characterization of peptide 1c 34
- Characterization of peptide 2b 36
- Characterization of peptide 2c 41
- Characterization of peptide 2d 46
- Characterization of peptide 2e 49
- Characterization of peptide 2f 54
- Characterization of peptide 2g 59
- Characterization of peptide 2h 64
- Characterization of peptide 2i 69

CHAPTER 3: A Tetramer Derived from Islet Amyloid Polypeptide 73

## Introduction

- Results and Discussion 77
- Conclusions 94
- Material and Methods 99
Characterization of peptide $1_{\text{Arg}}$ 105
Characterization of peptide $1_{\text{Cit}}$ 117
Characterization of peptide $2_{\text{Cit}}$ 147

CHAPTER 4: Effects of Charge and Hydrophobicity on the Oligomerization of a Peptide Derived from IAPP 154

Introduction 155
Results and Discussion 157
Conclusions 169
Material and Methods 172

Characterization of peptide $1_{\text{Glu}}$ 176
Characterization of peptide $1_{\text{Leu}}$ 204
Characterization of peptide $1_{\text{His}}$ 232

CHAPTER 5: My Teaching Experiences 260
# LIST OF FIGURES

<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Figure 1.1</td>
<td>Chemical structures of Hao-containing macrocyclic β-sheet peptides (top) and N-methyl macrocyclic β-sheet peptides (bottom)</td>
<td>3</td>
</tr>
<tr>
<td>Figure 1.2</td>
<td>Chemical structure of macrocyclic β-sheet peptides incorporating residues 11 – 17 IAPP</td>
<td>4</td>
</tr>
<tr>
<td>Figure 2.1</td>
<td>54-membered macrocyclic peptide designed by the Nowick lab to study amyloidogenic sequences</td>
<td>12</td>
</tr>
<tr>
<td>Figure 2.2</td>
<td>Chemdraw of peptide 1b dimer assembling in a non-shifted, antiparallel fashion as derived from the NOESY spectroscopy.</td>
<td>15</td>
</tr>
<tr>
<td>Figure 2.3</td>
<td>Macrocyclic β-sheet peptide 1c incorporating 4-iodophenylalanine for X-ray crystallography.</td>
<td>16</td>
</tr>
<tr>
<td>Figure 3.1</td>
<td>Cartoon representation and chemical structure of macrocyclic β-sheet 1</td>
<td>76</td>
</tr>
<tr>
<td>Figure 3.2</td>
<td>Chemical structures of peptides 1Arg and 1Cit</td>
<td>77</td>
</tr>
<tr>
<td>Figure 3.3</td>
<td>1H NMR spectra of peptide 1Arg at 4 mM and 8 mM and 50 mM CD3COOD and 50 mM CD3COONa buffer in D2O at 500 MHz and 298K</td>
<td>78</td>
</tr>
<tr>
<td>Figure 3.4</td>
<td>1H NMR spectra of macrocyclic β-sheet peptides 1Arg and 1Cit in 50 mM CD3COOD and 50 mM CD3COONa buffer in D2O at 298 K</td>
<td>79</td>
</tr>
<tr>
<td>Figure 3.5</td>
<td>Downfield shifting of the α-protons of peptide 1Arg at 4 mM relative to those of random coil chemical shifts</td>
<td>79</td>
</tr>
<tr>
<td>Figure 3.6</td>
<td>1H NMR spectra of peptide 1Cit various concentrations and 50 mM CD3COOD and 50 mM CD3COONa buffer in D2O at 500 MHz and 298K</td>
<td>80</td>
</tr>
<tr>
<td>Figure 3.7</td>
<td>Downfield shifting of the α-protons of peptide 1Cit at 16 mM relative to those of random coil chemical shifts</td>
<td>81</td>
</tr>
<tr>
<td>Figure 3.8</td>
<td>Chemical structure of peptide 2Cit with the leucine isostere, (2-bromoallyl)glycine residue in red</td>
<td>82</td>
</tr>
<tr>
<td>Figure 3.9</td>
<td>X-ray crystallographic structure of peptide 2Cit</td>
<td>83</td>
</tr>
<tr>
<td>Figure 3.10</td>
<td>X-ray crystallographic structure of the dimer formed by peptide 2Cit</td>
<td>84</td>
</tr>
</tbody>
</table>
Figure 3.11  X-ray crystallographic structure of the tetramer of peptide 2Cit  85
Figure 3.12  NOEs associated with the dimer subunit of peptide 1Cit  88
Figure 3.13  NOE associated with the tetramer of peptide 1Cit  89
Figure 3.14  Crystographically based molecular model of the tetramer formed by peptide 1Cit  91
Figure 3.15  Crystographically based molecular models of the dimer subunits of the tetramers of peptide 1Cit and 1Arg  92
Figure 3.16  Chemical structures of N-methylated macrocyclic β-sheet peptides and Hao-based macrocyclic β-sheet peptides  94

Figure 4.1  Tetramer formation of peptide 1Cit  156
Figure 4.2  Chemical structure of macrocyclic β-sheet peptides peptides 1Arg, 1Cit, 1Glu, 1Leu, and 1His with different residues at position 11  157
Figure 4.3  1H NMR spectra of macrocyclic β-sheet peptides 1Arg, 1Cit, 1Glu, and 1Leu in 50 mM CD3COOD and 50 mM CD3COONa buffer in D2O at 298 K  158
Figure 4.4  Percentage of tetrameric peptides 1Cit, 1Glu, and 1Leu at 1, 2, 4, and 8 mM. The values are derived from integrations of the Hao4 and Hao6 resonances of the tetramer and the monomer  160
Figure 4.5  1H NMR spectra of peptide 1Glu various concentrations and 50 mM CD3COOD and 50 mM CD3COONa buffer in D2O at 500 MHz and 298K  161
Figure 4.6  1H NMR spectra of peptide 1Glu various concentrations and 50 mM CD3COOD and 50 mM CD3COONa buffer in D2O at 500 MHz and 298K  162
Figure 4.7  NOEs associated with the dimer subunit of peptide 1Glu and 1Leu  165
Figure 4.8  Shifted, antiparallel hydrogen-bonded dimer of peptide 1Leu  166
Figure 4.9  1H NMR spectra of macrocyclic β-sheet peptides 1His  167
LIST OF TABLES

<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table 2.1</td>
<td>Macro cyclic β-sheet peptides 1a and 1b with Aβ_{17-23} as the heptapeptide top strand</td>
<td>12</td>
</tr>
<tr>
<td>Table 2.2</td>
<td>Macro cyclic β-sheet peptides 2a and 2i, with IAPP_{11-17} and a one-residue mutation of IAPP_{11} as the heptapeptide top strand</td>
<td>14</td>
</tr>
<tr>
<td>Table 2.3</td>
<td>Macro cyclic β-sheet peptides 2a–2g, with IAPP_{11-17} as the heptapeptide top strand</td>
<td>18</td>
</tr>
<tr>
<td>Table 2.4</td>
<td>Macro cyclic β-sheet peptide 2h with IAPP_{10-16} as the heptapeptide top strand and peptide 2i with IAPP_{11-17} as the heptapeptide top strand with a leucine mutation at Arg_{11}</td>
<td>20</td>
</tr>
<tr>
<td>Table 3.1</td>
<td>Diffusion coefficients (D) of peptides 1Arg and 1Cit in 50 mM CD_{3}COOD and 50 mM CD_{3}COONa buffer in D_{2}O at 298 K</td>
<td>87</td>
</tr>
<tr>
<td>Table 4.1</td>
<td>Δδ^{5}Orn values of peptides 1Arg, 1Cit, 1Glu, 1Leu, 1His in D_{2}O at 298 K</td>
<td>159</td>
</tr>
<tr>
<td>Table 4.2</td>
<td>Diffusion coefficients (D) of peptides 1Glu, 1Leu, 1His in D_{2}O at 298 K</td>
<td>164</td>
</tr>
</tbody>
</table>
I would like to express my deepest gratitude to my committee chair, Professor James Nowick, who is the best mentor a graduate student could hope for. In science, his unmatched attention to detail and passionate pursuit of scientific discussions motivated me to better myself. In everyday life, his respect for diversity, patience for his students, and willingness to put others before himself leaves me humbled. Without his support, I would not be the scientist and teacher that I am today.

I would like to thank my committee members, Professor Jennifer Prescher and Professor David Van Vranken, for mentoring me these past few years. Professor Jennifer Prescher was incredibly helpful with guiding me through my orals proposal and her chemical biology class was essential towards my development as a teacher. Without the knowledge from her class, I would not have been able to instruct the Chem 128 course. Professor David Van Vranken provided unparalleled support in my teaching career. When he discovered that I was teaching Chem 128 and Chem 51C, he allowed me to learn from the material that he prepared. I loved the Chem 201 class that he taught and have since applied the collaborative learning activities to my own classes.

I would like to thank the Nowick lab for being an inclusive and fun learning environment. I want to especially thank Nicholas Truex for his assistance with NMR spectroscopy and Adam Kreutzer for his assistance in X-ray crystallography. Nick and Adam provided me with support throughout my graduate career and I sincerely appreciate it. The Nowick lab is a wonderful group where ideas and creativity flourish due to constant communication, I could not have found a better lab.

I would like to thank all of the professors and staff in the UCI Department of chemistry. I thank Professor Greg Weiss for helping me grow as a teacher. I thank Dr. Phil Dennison for providing support for the NMR experiments. I will also like to thank the National Institute of Health and the National Science Foundation for supporting these projects.

Last, but not least, I would like to thank my family and my fiancé for their constant support. My family supported my decision to pursue my studies in a foreign country, even when it meant that I would be far away. My fiancé, Alexander Thuy-Boun, provided me with emotional support even when things were tough. It is thanks to them that I have the opportunity to grow and develop as a scientist.
CURRICULUM VITAE

Yilin Wang

Education

University of California, Irvine
Ph.D. Department of Chemistry. (Sep 2012 - present)
Thesis: Effects of Charge and Hydrophobicity on the Oligomerization of IAPP-Derived Peptides

University of Tennessee, Knoxville
Master of Science. Department of Chemistry (Aug 2012)
Thesis: Design and Synthesis of Boronic Acid-Based Sensors to Study Carbohydrates

University of Florida
Bachelor of Science, Biochemistry (Dec 2009)

Santa Fe College
Associate of Arts (April 2007)

Teaching Experience

University of California, Irvine
Instructor, Organic Chemistry, Chem 51C
Lecture enrollment: 370 students
Spring 2017

• Designed and taught two one-hour-and-twenty-minutes lectures a week to sophomore students.
• Integrated active learning activities applicable to large lecture sizes such as iClicker problems to address SLOs and think-pair-share to encourage discussions for collaborative learning.
• Prepared biweekly online homework sets to keep students apprised of their progress.
• Introduced Biology and Chemistry Online Notes (BACON) tutorials so students can relate course material to real world applications.
• Prepared weekly worksheets for discussion sections led by two teaching assistants.

Instructor, Introduction to Chemical Biology, Chem 128
Lecture enrollment: 26 students
Summer 2016

• Designed and taught three two-hour lectures a week to junior and senior students.
• Began each class with a list of Student Learning Objectives (SLOs) and installed example problems addressing SLOs throughout lecture
• Integrated active learning activities such as semi-flipped classroom to encourage student participation.
• Prepared weekly problem sets and quizzes to keep students apprised of their progress.
• Emphasized relevance of course material in real world applications with relatable examples.
• Designed end-of-term project to encourage students to explore scientific literature online and develop crucial scientific communications skills.
• Worked with a diverse population of students including international and ESL students, and taught strategies for reading scientific articles.

Graduate Course Teaching Assistant, Chemical Biology, Chem 219
Lecture and Discussion enrollment: 19 students
Winter, 2016
• Guest lectured two one-hour sessions during this course.
• Prepared biweekly problem sets derived from current, prominent publications.
• Led weekly discussions of hot topics in Chemical Biology.
• Assisted students in the construction of an original proposal in chemical biology.

Laboratory Course Teaching Assistant, Chemistry 1LD, 1LC, 51LB, 51LC
Lab enrollment: 20 students
Spring, 2016
• Taught students to keep complete and accurate scientific records.
• Supervised and instructed students in general and organic chemistry lab techniques.
• Held weekly student-led presentations to consolidate lab materials from the previous week.
• Began each lab section with a comprehensive overview of laboratory techniques, objectives, and safety precautions.

Lecture Course Teaching Assistant, General Chemistry 1A and 1C
Lecture enrollment: >300 students  Discussion enrollment: 70 students
Fall, 2015
• Head TA for Chem 1A, with duties such as supervising graders and one other teaching assistant.
• Prepared weekly problem sets in Chem 1A and contributed exam problems.
• Led discussions and assisted students individually with understanding concepts and homework problems.
• Held reviews for students and graded exams to provide students with helpful feedback.

Lecture Course Teaching Assistant, Organic Chemistry 51B and 51C
Lecture enrollment: >200 students  Discussion enrollment: 25 students
Spring, 2013
• Assisted in the preparation of teaching materials such as problem sets and exams.
• Led discussions of problems relating to organic chemistry topics using collaborative learning techniques.
• Held reviews for students and graded exams to provide students with helpful feedback.

University of Tennessee, Knoxville
Lecture and Laboratory Course Teaching Assistant, Chemistry 100 and 110
Fall 2010—Spring, 2012
• Led weekly discussions and supervised nursing students in basic chemistry lab techniques for Principles of Chemistry 100 and Introduction to Organic and Biochemistry 110.
• Prepared weekly worksheets for discussions to help students understand course material.
• Held reviews for students and graded exams to provide students with helpful feedback.

University and Community Services

Safety Representative

University of California, Irvine, Department of Chemistry
June 2014 — July 2017
• Achieved zero injury rate during this period with a lab of approximately 15 members.
• Conducted safety inspections to OSHA standards and reported findings at weekly safety meetings.
• Ensured safe practices in lab by verifying PPE compliance and updating SOPs.
• Worked closely with the Environmental Health & Safety department to implement new safety regulations.

Chemistry Outreach Participant

University of California, Irvine, Department of Chemistry
Jan 2016 — Jan 2017
• Visited K-12 schools to perform demonstration and talk about chemistry with a team of graduate students.
• Assisted with the preparation of chemicals required for conducting demonstrations.
• Increased the relevance of chemistry to students using lively demonstrations and interesting experiments.

Professional Development

Course Design Certificate

University of California, Irvine, Center of Engaged Instruction
Nov 2016
• This is a 3-week program that covers the foundations of successful course design with a focus on student learning outcomes (SLO).
• Practiced “backwards, integrated course design” by establishing goals for student learning and aligning assignments and assessments with these goals.

University Studies 390A, Advanced Pedagogy and Academic Job Preparation

University of California, Irvine, Center of Engaged Instruction
Winter 2017
• Introduction to principles of course design and instructional development.
• This course covers topics on active learning, learning through diversity, and educational research.

University Studies 390B, Advanced Pedagogy and Academic Job Preparation

University of California, Irvine, Center of Engaged Instruction
Spring 2017
• Application of US 390A material in the design and implementation of the Teaching Assistant Professional Development Program.
• Fellows design a workshop meant to model best teaching practices as well as introduce new TAs to their roles and responsibilities.

Center for Integration of Research, Teaching, and Learning Associate

University of California, Irvine, Center of Engaged Instruction
Winter 2017
• This program teaches graduate students and faculty to effectively implement research based practices in different learning environments.
• Participants are taught the importance of learning through diversity, learning communities and teaching as research.
• Designed a potential teaching as research project with definable goals and outcomes.

Research Experience

Graduate Research Assistant
University of California, Irvine, Department of Chemistry
Advisor: James Nowick
Currently developing β-sheet chemical models to study oligomers of human islet amyloid polypeptide, an amyloidogenic peptide that is associated in the pathology of type 2 diabetes.

Graduate Research Assistant
University of Tennessee, Knoxville, Department of Chemistry
Advisor: Michael Best
Worked on the design and synthesis of boronic acid-based sensors for microarray analysis and FRET-detection to study carbohydrates. (Jan 2011- Aug 2012)

Undergraduate Research Assistant
University of Florida, Department of Chemistry
Advisor: Marta Wayne
Worked on the study of virulence evolution in a host-parasite system in the absence of viral evolution.

Undergraduate Summer Researcher
University of Florida, Department of Chemistry
Advisor: Eileen Buss
Explored the effects of different pesticides to billbugs and turfgrass population.

Presentations


**Publications**


**Honors and Awards**

- Most Promising Future Faculty May 2017
  - This competitive award honors one graduate student for a record of distinguished teaching, and promising research.

- Pedagogical Fellowship Nov 2016
  - This competitive program is based on a record of excellent teaching, promising scholarship, and service to the University, department, and the disciplines’ professional community. The program is designed to provide Fellows with advanced pedagogical, pre-professional, and program development through course work, practice, and feedback.

- First Year Achievement Award, University of Tennessee, Knoxville Aug 2010
  - This competitive award honors three first year students for excellent teaching and distinguished academic performance.

- Dean’s Honor List (Santa Fe College) Aug 2005—Apr 2007
ABSTRACT OF THE DISSERTATION

Effects of Charge and Hydrophobicity on the Oligomerization of Macrocyclic β-Sheet Peptides derived from Islet Amyloid Polypeptide

By

Yilin Wang

Doctor of Philosophy in Chemistry

University of California, Irvine, 2017

Professor James Nowick, Chair

Aggregation of the islet amyloid polypeptide (IAPP) to form fibrils and oligomers is important in the progression of type 2 diabetes. This dissertation describes the effects of charge and hydrophobicity on the oligomerization of macrocyclic β-sheet peptides derived from IAPP. Incorporation of residues 11–17 of IAPP (RLANFLV) into a macrocyclic β-sheet peptide results in a monomeric peptide that does not self-assemble to form oligomers. Mutation of Arg11 to the uncharged isostere citrulline gives peptide homologues that assemble to form tetramers in both the crystal state and in aqueous solution (peptide \textit{1\textsubscript{Cit}}). The tetramers consist of hydrogen-bonded dimers that sandwich together through hydrophobic interactions. This dissertation also probes the role of charge and hydrophobicity by changing residue 11 to glutamic acid (peptide \textit{1\textsubscript{Glu}}) and leucine (peptide \textit{1\textsubscript{Leu}}). Diffusion ordered spectroscopy (DOSY) studies show that peptides \textit{1\textsubscript{Glu}} and \textit{1\textsubscript{Leu}} form tetramers in solution. NOESY studies confirm that both peptides formed the same sandwich-like tetramer as peptide \textit{1\textsubscript{Cit}}. $^1$H NMR spectroscopy at various concentrations reveal that peptide \textit{1\textsubscript{Leu}} has the highest propensity to form tetramers due to the leucine residue at
position 11 which contributes to packing. The effects of pH and charge on oligomerization are further probed by incorporation of histidine at position 11 (peptide 1\text{His}). DOSY studies show that peptide 1\text{His} forms a tetramer at high pH. At low pH, peptide 1\text{His} forms a new species that has not been observed by our group — a dimer. These studies demonstrate the importance of charge and hydrophobicity in the oligomerization of IAPP-derived peptides.
Chapter 1

Introduction
Interaction among β-sheets is important in the formation of amyloid oligomers, which are implicated in approximately 50 disorders.\(^1\)\(^-\)\(^4\) Tremendous interest in type II diabetes and Alzheimer's disease has emerged in recent years as they become increasingly common in the modern world.\(^2\)\(^,\)\(^5\)\(^-\)\(^7\) Islet amyloid polypeptide (IAPP) in type II diabetes and β-amyloid peptide (Aβ) in Alzheimer's disease aggregate to form toxic oligomers that are central to the progression of the diseases.\(^8\)\(^-\)\(^10\) Unfortunately, not much is known about the structure of the oligomers because high-resolution characterization proves challenging due to their polymorphic and heterogeneous nature.

To gain insight into the assembly of amyloid oligomers, research groups developed structural models by studying segments of full-length amyloidogenic peptides and proteins.\(^11\)\(^-\)\(^14\) Eisenberg and coworkers proposed an oligomeric assembly derived from αB crystallin, forming a barrel of six antiparallel β-sheets.\(^11\) Surewicz and coworkers described a hexameric oligomer derived from prion protein that assembled to form three four-stranded, antiparallel β-sheets arranged like the edges of a triangle.\(^12\) In the Nowick lab, we use macrocyclic β-sheet peptides containing fragments of amyloidogenic peptides and proteins as chemical models to study β-sheet interactions.\(^15\)\(^-\)\(^21\) Nicholas Truex of our group reported the solution phase assembly of Aβ homotetramers and heterotetramers using Hao-containing macrocyclic β-sheets.\(^18\)\(^,\)\(^19\) Adam Kreutzer of our group proposed the X-ray crystallographic structure of Aβ trimers and dodecamers using N-methyl macrocyclic β-sheet peptides (Figure 1.1).\(^20\) My research has focused on using these chemical model systems to gain insight into the structure of IAPP oligomers at high-resolution using NMR spectroscopy and X-ray crystallography.\(^22\)
Figure 1.1. Chemical structures of Hao-containing macrocyclic β-sheet peptides (top) and N-methyl macrocyclic β-sheet peptides (bottom).

In selecting the fragment of IAPP to study, I took into account its relevance to toxic oligomers and its β-sheet forming propensity.23,24 A proposed model on IAPP cytotoxicity shows that residues 1–19 are important as they are responsible for disrupting the lipid membrane.25,26 Although there are no high-resolution structures of the amyloid oligomers, they appear to be composed of β-sheets. Hoyer and coworkers proposed an NMR-based structure of an IAPP:affibody complex and suggested that the IAPP β-hairpin structure might be involved in IAPP aggregation.27 The β-hairpin comprises residues 12–28 where residues 12–18 and residues 22–28 form β-strands. Structural models of the IAPP fibrils also provide insight into IAPP sequences that have β-sheet forming propensities. Various research groups proposed structural models of IAPP fibrils where central residues 12–17 and C-terminal residues 31–36 are typically involved in β-strand formation.28-30 I began my research by incorporating residues 11–17 of IAPP into a Hao-containing macrocyclic β-sheet peptide.

The macrocyclic β-sheet peptide contains the heptapeptide strand from IAPP (RLANFLV) and a template strand that are connected by two δ-linked ornithine (δOrn) turn units (Figure 1.2).31 The template strand contains the unnatural amino acid Hao, which mimics a
tripeptide β-strand, templates β-sheet formation, and blocks uncontrolled aggregation. The template strand also contains four additional α-amino acids, with two residues flanking each side of Hao. These four residues are used to reinforce the hydrophobic surface and increase solubility of the macrocyclic β-sheet peptide. In the current study, my original aim was to study the interaction of amyloid oligomers of IAPP.

Initial studies of the IAPP-derived macrocyclic β-sheet peptides with varying R8–R11 residues show no oligomer information (Chapter 2). The lack of oligomerization was surprising as a homologous region of Aβ residues 17–23, LVFFAED, forms a tetramer when constrained in a macrocyclic β-sheet peptide. The tetramer consists of a sandwich of hydrogen bonded dimers that pack on their hydrophobic surface containing leucine, phenylalanine, alanine, and aspartic acid. Both heptapeptide sequences contain three nonpolar residues and an additional polar residue on the hydrophobic surface. The tetramerization of Aβ-derived macrocyclic β-sheet peptide sparked my curiosity as to why the IAPP-derived macrocyclic β-sheet peptides were not self-assembling.

I focused my attention on the arginine residue as it has a positive charge that is not present on the Aβ sequence. To study the effects of arginine on oligomerization, I mutated it to the neutral isostere citrulline that contains a urea group in place of the guanidinium group.
NMR spectroscopy shows that the mutant peptide, like the Aβ-derived peptide, forms a tetramer in solution. The formation of a tetramer was interesting, as it demonstrated that charge can modulate oligomerization. To gain further insight into the structure of the tetramer, I decided to pursue X-ray crystallography of the mutant peptide. Obtaining a suitable crystal offered some unique challenges. Screening the peptide in 864 conditions revealed one promising condition with cubic crystal growth. Incorporation of a heavy atom in the form of p-iodo-phenylalanine at position 15 for single-wavelength anomalous dispersion phasing led to poor crystal quality. I hypothesized that the poor crystal quality is due to the importance of the phenylalanine residue in assembly. Therefore, I opted to use (2-bromoallyl)glycine to replace the isoleucine residue on the template strand which yielded a suitable crystal. In chapter 3, I describe the assembly of the crystal structure and correlated it to the assembly of the mutant peptide in solution.

Inspired by the role of charge in oligomerization, I wanted to ask two questions: Can pH modulate oligomerization and does hydrophobicity affect oligomerization? In many biological processes, pH triggers a conformational change in protein structure. Histidine residues are often involved because their protonation state changes near physiological pH. I designed a macrocyclic β-sheet peptide that incorporates residues 11–17 of IAPP with a histidine mutation at position 11. I detail the studies of the His-containing peptide in Chapter 4, showing that charge can modulate oligomerization. To probe the effects of hydrophobicity on oligomerization, I designed additional mutants containing either glutamic acid or leucine at position 11. NMR studies show that both of these mutant peptides form tetramers, but there are differences in their propensities to form tetramers. I compare and contrast the properties of the mutant peptides in Chapter 4, offering insight into the interaction of β-sheets.
The study of IAPP-derived macrocyclic β-sheet peptides demonstrated that charge and hydrophobicity are important in oligomerization. Additional studies of other sequences of IAPP using Hao-containing macrocyclic β-sheets and N-methyl macrocyclic β-sheets shows no formation of discrete oligomers at low millimolar concentrations. The lack of self-assembly may be due to the many hydrophilic residues that are present in the IAPP sequence. Unlike Aβ, IAPP does not have long consecutive sequences of hydrophobic residues. In the future, one could envision increasing the number of residues incorporated as a potential modification to our current chemical model for the study of IAPP.
References


Chapter 2

Design of Macro cyclic $\beta$-Sheet Peptides Associated with Amyloid $\beta$ and Islet Amyloid Polypeptide
Introduction

The accumulation of misfolded \( \beta \)-sheet into protein aggregates has been associated with the pathology of over 20 diseases, such as Alzheimer’s disease and diabetes mellitus type 2.\(^{1-3} \) In Alzheimer’s disease, the \( \beta \)-amyloid peptide (A\( \beta \)) causes neuronal death in brain tissues.\(^{4-6} \) In diabetes mellitus type II, the misfolded human islet amyloid polypeptide (IAPP or amylin) results in \( \beta \)-cell death in the pancreas.\(^{7-10} \) In all these diseases, the aggregation process involves the formation of insoluble amyloid fibrils and cytotoxic amyloid oligomers.\(^{4,10,11} \) Studies show that patients with type 2 diabetes have a higher chance of developing Alzheimer’s disease and vice versa.\(^{12-16} \) The process of cross seeding, the aggregation of one protein promoting the aggregation of another, could be because A\( \beta \) and IAPP exhibit 25\% sequence identity and 50\% sequence similarity. The specificity in cross seeding may be the consequence of biomolecular recognition resulting from the hydrophobic interactions and hydrogen bonding between protein \( \beta \)-sheets.

Extensive research efforts have been made over the past several years to comprehend the biomolecular basis of amyloid diseases.\(^{17-19} \) In amyloidogenic diseases, the respective peptide misfolds and forms the toxic oligomers, which are in equilibrium with the fibers.\(^{4} \) Despite decades of research, it is not yet clear how these oligomers result in disorders and understanding these amyloid interactions is necessary for therapeutic advances. To shed light on the assembly of the oligomers, the Nowick lab uses chemical models (Figure 2.1) to study particular amyloidogenic segments with a propensity to form intermolecular \( \beta \)-sheet network.\(^{20-30} \) The upper strand (\( R_{1-7} \)) of the macrocycle contains a heptapeptide sequence that is often a native amyloidogenic sequence. The lower strand contains the molecular template “Hao” a tripeptide \( \beta \)-sheet mimic, which prevents uncontrollable aggregation, and effectively induces \( \beta \)-sheet
interactions. Two ornithine turn-units connect the upper and lower strands and the macrocycle comes together with intramolecular hydrogen bonding. This chapter describes the design of macrocyclic β-sheet peptides to study the assembly of amyloidogenic sequences.

**Figure 2.1.** 54-membered macrocyclic peptide designed by the Nowick lab to study amyloidogenic sequences.

**Table 2.1.** Macrocyclic β-sheet peptides 1a and 1b with Aβ17-23 as the heptapeptide top strand. The bottom strand shows the swapping of the hydrophobic/hydrophilic residue positions. Peptide 1b is designed as a defined oligomer to study Aβ17-23 interactions. Peptide 1a has been previously published.

<table>
<thead>
<tr>
<th></th>
<th>R₈</th>
<th>R₉</th>
<th>R₁₀</th>
<th>R₁₁</th>
</tr>
</thead>
<tbody>
<tr>
<td>1a</td>
<td>Lys</td>
<td>Leu</td>
<td>Ile</td>
<td>Glu</td>
</tr>
<tr>
<td>1b</td>
<td>Ile</td>
<td>Lys</td>
<td>Lys</td>
<td>Ile</td>
</tr>
</tbody>
</table>
Former Nowick group member, Dr. Pin-Nan Cheng developed the 54-membered macrocyclic peptide chemical model, peptide 1a, to study its ability to inhibit amyloid aggregation (Table 2.1).\textsuperscript{20} The upper strand (R\textsubscript{1-7}) of the macrocycle contains the native heptapeptide sequence LVFFAED derived from Aβ\textsubscript{17-23} as the sequence of interest. The Lys\textsubscript{8} and Glu\textsubscript{11} on the bottom strand of 1a are hydrophilic residues that reduce oligomerization. Structural studies with NMR spectroscopy show that the macrocycle exists in solution as a monomer.

Modifications of this design to form defined oligomers turned into an exciting project to study the molecular recognition between the N-terminus and C-terminus of the Aβ protein. For this project we incorporate Aβ\textsubscript{17-23} sequence LVFFAED and Aβ\textsubscript{30-36} sequence AIIGLMV into macrocyclic β-sheets to study their propensity to homo- and heterooligomerize. We have developed these macrocyclic β-sheets as chemical models for the oligomerization of amyloidogenic sequences.

My involvement in the project focuses on the design, synthesis, and characterization of peptide 1b (Table 2.1).\textsuperscript{27} In order to promote oligomerization, I placed hydrophobic residues at R\textsubscript{8} and R\textsubscript{11} instead of at R\textsubscript{9} and R\textsubscript{10}. This switch places upper strand Leu\textsubscript{17}, Phe\textsubscript{19}, Ala\textsubscript{21}, and Glu\textsubscript{23} residues and bottom strand Ile\textsubscript{8} and Ile\textsubscript{11} residues on the same hydrophobic surface for molecular recognition. This peptide and its derivatives were used for NMR analysis to study homo- and heterooligomerization of the N- and C-terminal regions of Aβ.\textsuperscript{27,28}

To study the fundamental principles in the molecular recognition of amyloidogenic sequences of IAPP, I designed macrocyclic β-sheet peptides containing a heptapeptide segment of IAPP. Previously, Dr. Pin-nan Cheng designed peptide 2a as a monomer to study its properties as an amyloid inhibitor (Table 2.2).\textsuperscript{20} The upper strand of the peptide contains the central native heptapeptide sequence RLANFLV derived from IAPP\textsubscript{11-17} as the sequence of
interest. I made a series of macrocycles based on peptide 2a to study the self-assembly of IAPP$_{11-17}$ into an oligomer.

Table 2.2. Macrocyclic β-sheet peptides 2a and 2i, with IAPP$_{11-17}$ and a one-residue mutation of IAPP$_{11}$ as the heptapeptide top strand. The bottom strand shows the swapping of the hydrophobic/ hydrophilic residue positions. 2i was designed to be a defined oligomer to study the effect of arginine. Peptide 2a has been previously published.

<table>
<thead>
<tr>
<th></th>
<th>R$_1$</th>
<th>R$_8$</th>
<th>R$_9$</th>
<th>R$_10$</th>
<th>R$_{11}$</th>
</tr>
</thead>
<tbody>
<tr>
<td>2a</td>
<td>Arg</td>
<td>Lys</td>
<td>Phe</td>
<td>Tyr</td>
<td>Lys</td>
</tr>
<tr>
<td>2i</td>
<td>Leu</td>
<td>Ile</td>
<td>Lys</td>
<td>Val</td>
<td>Ile</td>
</tr>
</tbody>
</table>

Results and Discussion

I carried out the synthesis and purification of macrocycles according to published procedures.$^{33}$

The corresponding linear peptides were synthesized using standard Fmoc-based solid phase peptide synthesis (SPPS) on 2-chlorotrityl resin. The protected linear peptides were cleaved from the resin, cyclized in solution, then globally deprotected to generate the 54-membered macrocyclic β-sheet peptide. The peptides were purified by reversed-phase high-performance liquid chromatography (RP-HPLC) and lyophilized to give 10-40 mg of the peptide as a TFA salt. Analysis by mass spectrometry and HPLC show that the purity was >95%.

$^1$H NMR structural studies in aqueous solutions provide detailed knowledge on oligomerization and β-sheet properties. $^1$H NMR and the accompanying 2D NMR results provide assignment of the respective peptide residues. The $^1$H NMR of peptide 1b at 4 mM shows that the resonances are broader and the α-protons are shifted downfield by 0.4–1.0 ppm from their
random coil values. The large downfield chemical shifts of the α-protons in peptide 1b demonstrates packing of the macrocyclic β-sheet peptides. In addition, the upfield shifting of the aromatic resonances of the Phe residue from its random coil values indicates aromatic packing.

In the 1H NMR spectrum, the difference in the chemical shifts of the diastereotopic δ-protons of an ornithine turn unit (ΔδORN) is an indication of the degree of folding of the peptide. Previous studies of homologous macrocycles have shown that a value of 0.6 ppm indicates complete folding in water.²¹ The average ΔδORN value of peptide 1b is 0.68 ppm, indicating a β-sheet structure.

NOESY studies of the macrocycle oligomer display a network of NOEs that show an in-register edge-to-edge dimerization through antiparallel β-sheet formation. Intramolecular NOEs (Figure 2.2) are observed between the α-proton of Glu$_{22}$ and Lys, between the α-proton of Phe$_{19}$ and the proton at the 6-position of Hao, and between the α-proton of Val$_{18}$ and Lys indicating formation of a β-sheet. Intermolecular NOEs are observed between the α-proton of Leu$_{17}$ and Asp$_{23}$, and between the α-proton of Phe$_{19}$ and Ala$_{21}$ indicating edge-to-edge, in-register, antiparallel dimerization.

![Figure 2.2](Image)

**Figure 2.2.** Chemdraw of peptide 1b dimer assembling in a non-shifted, antiparallel fashion as derived from the NOESY spectroscopy.
NMR diffusion experiments such as DOSY provide a way to distinguish between the different species based on the diffusion coefficient peptides. The ratio of the diffusion coefficient of the oligomer to the monomer \( \left( \frac{D_{\text{oligomer}}}{D_{\text{monomer}}} \right) \) is a representation of the oligomerization state.\(^{23,27,28}\) For a tetramer, this value is approximately 0.58–0.63 and for a dimer, this value is approximately 0.75–0.79. Measurement of the diffusion coefficients taken from DOSY experiments of peptide 1b indicates the presence of a single oligomeric species. The \( D_{\text{oligomer}} \) of peptide 1b is \((11.1 \pm 1.0) \times 10^{-7} \) m\(^2\)/s but \( D_{\text{monomer}} \) cannot be obtained, as peptide 1b forms a tetramer even at low concentrations. The diffusion coefficient of a monomeric control macrocyclic peptide within 10% molecular weight of peptide 1b is used. \( D_{\text{monomer}} \) is \((17.6 \pm 1.0) \times 10^{-11} \) m\(^2\)/s. The ratio of diffusion coefficients for peptide 1b is 0.63 suggesting that it is a tetrameric oligomer in water.

X-ray crystallography is a viable platform for crystal-state structural determination complementary to NMR in solution-state structural determination. Based on previous studies in our lab, an X-ray crystallographic structure can offer more information about the solution-phase structure in addition to NMR.\(^{34}\) Phase determination of the X-ray crystallography is done by single anomalous dispersion (SAD), which requires the incorporation of a heavy atom to solve the crystal structure.\(^{22}\) The heavy atom is incorporated hboin the form of 4-iodophenylalanine in position R₃ to give peptide 1c.

![Figure 2.3. Macrocyclic β-sheet peptides 1c incorporating 4-iodophenylalanine for X-ray crystallography.](image_url)
The process of finding a crystal suitable for X-ray crystallography can be the hardest step. The synthesized peptide undergoes pre-crystallization test (PCT) to determine the optimum concentration for crystal formation followed by high-throughput screening with 288 conditions such as buffers and polyethylene glycol (PEG) at different pH and concentrations. Select conditions that yield crystal growth were then optimized for best crystal growth by varying the concentration of salts and pH. Peptide 1c was synthesized because peptide 1b was believed to assemble on the L_{17}, F_{19}, A_{21}, and D_{23} hydrophobic face in solution-state and having the heavy atom on the hydrophobic face would cause less interference (Figure 2.3). The morphology of the crystals obtained from screening of peptide 1c showed poor growth with needles of various sizes. These crystals presented poor X-ray diffraction patterns, indicating that peptide 1c is not an appropriate candidate for X-ray crystallography. For future studies, 4-iodophenylalanine can replace the Phe_{20} residue to screen for suitable x-ray crystallography candidates.

The macrocyclic β-sheet peptides can be extended to the study of the oligomerization of IAPP-derived macrocycles, which can provide valuable insight on IAPP oligomers. When I first joined the lab, I designed peptides 2b-2d by transposing different residues in the bottom strand of 2a to promote oligomerization and learn about β-sheet folding (Table 2.3). $^1$H NMR spectroscopic data of the peptides provide detailed knowledge on oligomerization and β-sheet properties. A signature pattern of an oligomer is to have a series of α-protons peaks downfield of the HOD and the spectra peaks are generally much broader. The $^1$H NMR spectrum of each of the above compounds at 4 mM in D$_2$O showed that there were hardly any change in chemical shifts of their α-protons from their random coil values and the peaks were sharp and distinct, indicating that they were monomers. Peptide 2a has hydrophilic residues at R_8 and R_{11} that promote the formation of a monomer. Thus, it is not surprising that peptide 2b and 2c, which
both have hydrophilic edge-residues, were monomers. On the other hand, the lower strand of peptide 2d is flanked by 2 hydrophobic residues, Tyr$_8$ and Phe$_{11}$, which can promote oligomerization. The lack of oligomer formation suggests that aromatic residues do not pack well with the upper strand for the formation of an oligomer.

Table 2.3. Macro cyclic β-sheet peptides 2a–2g, with IAPP$_{11-17}$ as the heptapeptide top strand. The bottom strand shows the transposing of the hydrophobic/ hydrophilic residue positions. Peptide 2a has been previously published.

<table>
<thead>
<tr>
<th></th>
<th>R$_8$</th>
<th>R$_9$</th>
<th>R$_{10}$</th>
<th>R$_{11}$</th>
<th>Δ Orn (ppm)</th>
<th>β-sheet folding</th>
</tr>
</thead>
<tbody>
<tr>
<td>2a*</td>
<td>Lys</td>
<td>Phe</td>
<td>Tyr</td>
<td>Lys</td>
<td>0.50</td>
<td>+</td>
</tr>
<tr>
<td>2b</td>
<td>Lys</td>
<td>Tyr</td>
<td>Lys</td>
<td>Phe</td>
<td>0.44</td>
<td>+</td>
</tr>
<tr>
<td>2c</td>
<td>Tyr</td>
<td>Lys</td>
<td>Phe</td>
<td>Lys</td>
<td>0.16</td>
<td>-</td>
</tr>
<tr>
<td>2d</td>
<td>Tyr</td>
<td>Lys</td>
<td>Lys</td>
<td>Phe</td>
<td>0.19</td>
<td>-</td>
</tr>
<tr>
<td>2e</td>
<td>Ile</td>
<td>Lys</td>
<td>Lys</td>
<td>Ile</td>
<td>0.26</td>
<td>-</td>
</tr>
<tr>
<td>2f</td>
<td>Ile</td>
<td>Lys</td>
<td>Thr</td>
<td>Ile</td>
<td>0.37</td>
<td>+</td>
</tr>
<tr>
<td>2g</td>
<td>Ile</td>
<td>Thr</td>
<td>Val</td>
<td>Ile</td>
<td>0.60</td>
<td>++</td>
</tr>
</tbody>
</table>

Applying the same oligomerizing principles from peptide 1b containing Aβ$_{17-23}$, I decided to use the same bottom strand from peptide 1b to promote oligomerization by eliminating the aromatic residues (peptide 2e). Previous macrocycles that oligomerized are relatively hydrophobic, so I mutated R$_{10}$ from Lys to Thr (peptide 2f) to increase the hydrophobicity by removing a positive charge. To further investigate the effect of bottom strand hydrophobicity on oligomerization, I removed another charge by doubly mutating the Lys of peptide 2e at positions R$_9$ and R$_{10}$ to Thr and Val respectively (peptide 2g). The NMR spectrum of each of the compounds at 4 mM in D$_2$O showed sharp and distinct peaks, and the chemical shifts of their α-
protons showed only small shifts from their random coil values, indicating that they are monomers. Tabulation of $\Delta^{5}$Orn values shows that a more hydrophobic bottom strand promotes better folding of macrocyclic $\beta$-sheets. In peptides 2e-2g, the Arg$_1$, Ala$_3$, Phe$_5$, Val$_7$, Ile$_8$, and Ile$_{10}$ are on the same face but they do not pack appropriately to form a hydrophobic core that promotes oligomerization. The only hydrophilic residue on this surface is Arg and I postulate that the positive charge on the residue may be the cause of the monomeric nature of peptides 2b-2g.

To corroborate the above hypothesis that the upper strand was not suitable for the formation of an oligomer, the top strand native heptapeptide sequence was shifted one residue towards the N-terminus to give QRLANFL as the native heptapeptide upper strand (Table 2.4). The removal of a charge in the outer edge of the top strand may promote oligomerization. The NMR spectrum of peptide 2h at 4 mM in D$_2$O showed that there were generally only small changes in chemical shifts of its $\alpha$-protons from their random coil values and the peaks were sharp and distinct, indicating that peptide 2h is a monomer. In peptide 2h, Gln$_{10}$, Leu$_{12}$, Asn$_{14}$, Leu$_{16}$, Ile$_8$, and Ile$_{11}$ are on the same face and this arrangement places two polar hydrophilic residues on the hydrophobic face as opposed to one charged hydrophilic residue on the hydrophobic face. The lack of oligomer formation suggests that removal of a charge in the form of Arg$_{11}$ by shifting the heptapeptide sequence is insufficient because this introduces 2 hydrophilic residues, Gln$_1$ and Asn$_5$, to the packing surface.
Table 2.4. Macrocyclic β-sheet peptide 2h with IAPP_{10-16} as the heptapeptide top strand and peptide 2i with IAPP_{11-17} as the heptapeptide top strand with a leucine mutation at Arg_{11}. Peptide 2h is a monomer whereas peptide 2i is an oligomer.

<table>
<thead>
<tr>
<th></th>
<th>Δδ Orn (ppm)</th>
<th>β-sheet folding</th>
<th>Oligomer Formation</th>
</tr>
</thead>
<tbody>
<tr>
<td>2h</td>
<td>0.13</td>
<td>-</td>
<td>No</td>
</tr>
<tr>
<td>2i</td>
<td>0.68</td>
<td>+++</td>
<td>Yes</td>
</tr>
</tbody>
</table>

To better understand the effect of the positive charge on the upper strand, I modified the native IAPP sequence by mutating the Arg_{11} residue to Leu_{11} (peptide 2i). The Leu_{11} residue lacks the positive charge of the Arg_{11} residue, which I believe is preventing the formation of oligomers. The ^1H NMR spectrum at 4 mM in D_2O shows that the α-protons peaks are shifted downfield of the HOD and the spectra is much broader with less distinct sharp peaks. This shift indicates that peptide 1b is an oligomer and assumes a β-sheet structure. Oligomerization of peptide 2h supports my hypothesis that the Arg residue is inhibiting self-association of peptides.
Conclusions

The solution-state assembly of peptide 1b provided interesting insights into the formation of oligomers using our chemical models. By swapping the hydrophobic residues and hydrophilic residues in the lower strand of peptide 1a, peptide 1b promoted the formation of an oligomer for molecular recognition. Structural analysis using 1H NMR show that peptide 1b is a well-behaved, edge-to-edge, in-register, antiparallel tetramer that assembles on the hydrophobic surface.

Peptides 2b-2i were synthesized to study the central residue of IAPP, IAPP11-17, and the original purpose of the project is to understand the biomolecular recognition by the formation of an oligomer. However, this proves to be challenging as the charged Arg residue in the upper strand is preventing oligomerization. The mutation of the Arg amino acid to Leu resulted in the formation of an oligomer, further supporting my hypothesis that the Arg residue is inhibiting oligomerization. Chapters 3 and 4 further explores this interesting hypothesis.

As mentioned in the introduction, patients with Alzheimer’s are more likely to contract type 2 diabetes and vice versa. Thus, future studies of this biomolecular interaction could possibly help us better understand the cross-fibrillation of Aβ peptide and IAPP.
References


(6) Lesne, S. E.; Sherman, M. A.; Grant, M.; Kuskowski, M.; Schneider, J. A.; Bennett, D. A.; Ashe, K. H. *Brain* 2013, 136, 1383-1398.


Material and Methods

Fmoc-protected amino acids, 2-chlorotrityl resin, and coupling reagents—HOBT, HBTU, HCTU, HATU, were purchased from GL Biosciences Shanghai, LC Science, AnaSpec, Chem Impex, and Novabiochem. NMR solvents, D$_2$O, DMSO, and CDCl$_3$ were purchased from Cambridge Isotope Laboratories. HPLC grade solvents—acetonitrile, dichloromethane, hexanes, and tetrahydrofuran, were purchased from Fisher Scientific. Triisopropylsilane, N-methylmorpholine, trifluoroacetic acid, diisopropylethylamine (DIPEA), and 2,4,6-trimethylpyridine were purchased from Sigma-Aldrich. Polyprep chromatography columns were purchased from Bio-Rad. Fmoc-Hao-OH was synthesized based on published procedures.$^1$

Synthesis of macrocyclic peptides

1. Boc-Orn(Fmoc)-OH, 2,4,6 collidine, DCM
2. Successive Fmoc-protected amino acid couplings
3. 1:4 HFIP/DCM

Synthesized linear peptide

1. HBTU (5 eq.), HOBt (5 eq.), DIPEA (14 eq.)
2. TFA/TIPS/H$_2$O (18:1:1)
3. Purification by RP-HPLC
4. Lyophilization

Macrocycle as TFA salt
2-Chlorotrityl resin (0.300 g, 1.14 mmol/g, 0.100 mmol) was added to a polyprep column and swelled in dichloromethane (DCM) for 30 minutes before the solution was drained. The resin was then loaded overnight with Boc-Orn(Fmoc)-OH (81.8 mg, 0.18 mmol) dissolved in 5% 2,4,6-collidine in DCM (10 mL). 8 hours later, the resin was drained and capped with 17:2:1 DCM/MeOH/DIPEA. The resin was then used for automated peptide synthesis on the PS-3 Peptide Synthesizer from Protein Technologies, Inc. Each vial used for automated synthesis contained Fmoc-protected amino acid (0.468 mmol, 4.00 equiv) and HCTU (0.468 mmol, 4 equiv). Cleavage of the synthesized linear peptide from the resin was done using 1:4 HFIP/DCM. The linear peptide was then cyclized for 12 hours using HBTU (5 equiv), HBTU (5 equiv), and diisopropylethylamine (14 equiv) at around 1 mM in DMF to give the protected cyclized peptide. A 18:1:1 TFA/TIPS/H2O mixture was used to globally deprotect the macrocycle.

**Purification**

Peptides were analyzed for purity using analytical reversed-phase HPLC in an Agilent Zorbax SB-C18 column (50 mm x 4.6 mm), detection was set to 214 nm. A gradient of 5-95% CH3CN with 0.1% TFA in H2O with 0.085% TFA with a flow of 1.0 mL/min over 20 min was the method used for analysis. The peptides were purified using preparative reverse-phased HPLC on a Zorbox SB-C18 PrepHT (21.2 mm × 250 mm, 7 µm particle size) column from Agilent with the Beckmann system, detection is also set to 214 nm. H2O and CH3CN both contains 1% TFA. Mass spectrometry (MS) using electrospray ionization (ESI) is used to confirm the identity of the peptide.
Characterization

HPLC, mass spectrometry, and NMR spectroscopy are used in the characterization of macrocycles (HPLC and mass spectrometry described in the purification section). $^1$H, TOCSY, NOESY, ROESY were recorded on a Varian 800 MHz spectrometer. The $^1$H spectra were taken with 128 scans and with preset conditions as needed. The TOCSY and ROESY were acquired with 70 ms mixing time and NOESY was acquired with 150 ms mixing time. Diffusion-Ordered Spectroscopy was performed using a Bruker 500 MHz cryoprobe instrument. Data was processed using XwinNMR and TopSpin.

References

HPLC, MS ESI$^+$ TOF, and NMR ($^1$H, TOCSY and NOESY) of peptide 1b

Calculated $m/z$ for C$_{85}$H$_{130}$N$_{20}$O$_{21}$:
- [M+3H]$^3+$: 589.99
- [M+2H+Na]$^3+$: 597.33
- [M+2H+K]$^3+$: 602.66
- [M+H+2Na]$^3+$: 604.65
Varian 800MHz
NOESY with water suppression
150ms mixing time
Varian 800MHz NOESY with water suppression 150ms mixing time

Current Data Parameters

USER             yilinw
NAME     YW_i_LVFFAED_4mM_800_5
EXPNO                 4
PROCNO                1

F2 - Acquisition Parameters
Date_          20130830               Time               0.00               INSTRUM          varian               PROBHD   40:5mmbroadban
PULPROG           noesy               TD                 4096               SOLVENT             D2O               NS                    8               DS     128               DW               56.831 usec          DE                 6.00 usec          TE                298.0 K

F1 - Acquisition parameters
ND0                   1               TD                  512               SFO1           799.7986 MHz           FIDRES        17.183548 Hz            SW               11.000 ppm           FnMODE        undefined

F2 - Processing parameters
SI                 2048               SF          799.7948969 MHz           WDW               QSINE               SSB     2               LB                 0.00 Hz            GB                    0               PC                 1.40

F1 - Processing parameters
SI                 1024               MC2              States               SF          799.7948969 MHz           WDW     2               QSINE               SSB                   2               LB                 0.00 Hz            GB                    0

2D NMR plot parameters
CX2               15.00 cm
CX1               15.00 cm
F2PLO             5.500 ppm           F2LO            4398.87 Hz            F2PHI            -0.502 ppm           F2HI    5.500 ppm        ppm/cm        F2HZCM        320.00470 Hz/cm         F1PPMCM         0.40000 ppm/cm        F1HZCM        319.91797 Hz/cm
Varian 800MHz
NOESY with water suppression
150ms mixing time
HPLC, MS ESI\(^+\) TOF, and NMR \(^1\)H, TOCSY and ROESY) of peptide 1c

peptide structure

Calculated m/z for C\(_{85}\)H\(_{129}\)N\(_2\)O\(_{21}\): [M+2H]\(^+\) 947.44
[M+3H]\(^+\) 631.96
HPLC, MS ESI$^+$ TOF, and NMR ($^1$H, TOCSY and ROESY) of peptide 2b

Calculated $m/z$ for C$_{89}$H$_{134}$N$_{24}$O$_{19}$:
- [M+2H]$^{2+}$: 922.52
- [M+3H]$^{3+}$: 615.35
- [M+4H]$^{4+}$: 461.76

Calculated $m/z$ for C$_{88}$H$_{134}$N$_{24}$O$_{10}$:
- [M+2H]$^{2+}$: 922.52
- [M+3H]$^{3+}$: 615.35
- [M+4H]$^{4+}$: 461.76
HPLC, MS ESI$^+$ TOF, and NMR ($^1$H, TOCSY and ROESY) of peptide 2c

calculated $m/z$ for C$_{89}$H$_{134}$N$_{24}$O$_{19}$:

- [M+2H]$^{2+}$: 922.52
- [M+3H]$^{3+}$: 615.35
- [M+4H]$^{4+}$: 461.76
Current Data Parameters

**NAME** 20130807_YW_1_72_800
**USER** yilinw

**F2 - Acquisition Parameters**
- Date: 20130807
- Time: 0.00
- INSTRUM: varian
- PROBHD: 40:mmbroadban
- PULPROG: tocsy
- TD: 4096
- NS: 8
- DS: 16
- SW: 8797.977 Hz
- AQ: 0.2328308 sec
- RG: 287.4
- DW: 56.831 usec
- DE: 6.00 usec
- TE: 298.0 K

**F1 - Acquisition parameters**
- ND0: 1
- TD: 1024
- SFO1: 799.7986 MHz
- FIDRES: 8.591774 Hz
- SW: 11.000 ppm
- FNMODE: undefined

**F2 - Processing parameters**
- SI: 2048
- SF: 799.7947838 MHz
- WDW: QSINE
- SSB: 2
- LB: 0.00 Hz
- GC: 0
- PC: 1.40

**F1 - Processing parameters**
- SI: 1024
- MC2: States
- SF: 799.79838 MHz
- WDW: QSINE
- SSB: 2
- LB: 0.00 Hz
- GB: 0

2D NMR plot parameters
- CX2: 15.00 cm
- CX1: 15.00 cm
- CPX: 10.505 ppm
- CPY: 8212.41 Hz
- CPZ: -0.73 ppm
- CPX2: -585.57 Hz
- CPY2: 0.73 ppm/cm
- CPZ2: 586.5317 Hz/cm
- CPX3: 586.5317 Hz/cm
- CPY3: 586.5317 Hz/cm
- CPZ3: 586.5317 Hz/cm
HPLC, MS ESI$^+$ TOF, and NMR (\textsuperscript{1}H, TOCSY and ROESY) of peptide 2d

calculated m/z for C\textsubscript{89}H\textsubscript{134}N\textsubscript{24}O\textsubscript{19}:

[M+2H]$^+$: 922.52

[M+3H]$^+$: 615.35

[M+4H]$^+$: 461.76
Val H\textsubscript{a}

Orn\textsuperscript{1} H\textsubscript{a}, Orn\textsuperscript{2} H\textsubscript{a}

Ala H\textsubscript{a}

Leu H\textsubscript{a}

Arg H\textsubscript{a}

Lys H\textsubscript{a}

Lys H\textsubscript{a}

Leu H\textsubscript{a}

Tyr H\textsubscript{a}

Phe H\textsubscript{a}

Phe H\textsubscript{a}

Asn H\textsubscript{a}

H\textsubscript{aqOMe}

48
HPLC, MS ESI$^+$ TOF, and NMR ($^1$H, TOCSY and ROESY) of peptide 2e

Calculated m/z for C$_{80}$H$_{130}$N$_{22}$O$_{19}$:

- [M+2H]$^2+$: 852.50
- [M+3H]$^3+$: 568.67
HPLC, MS ESI+ TOF, and NMR (\(^1\)H, TOCSY and ROESY) of peptide 2f

Calculated m/z for C\(_{81}\)H\(_{133}\)N\(_{23}\)O\(_{19}\):

- \([M+2H]^{2+}: 867.01\)
- \([M+3H]^{3+}: 578.35\)
HPLC, MS ESI$^+$ TOF, and NMR ($^1$H, TOCSY and ROESY) of peptide \(2g\)

Calculated m/z for C\(_{80}\)H\(_{130}\)N\(_{22}\)O\(_{19}\):

- [M+2H]\(^{2+}\): 852.50
- [M+3H]\(^{3+}\): 568.67
Varian 800MHz
TOCSY with water suppression
70ms spinlock mix time

Current Data Parameters
[Table]

2D NMR plot parameters
[Table]
Varian 800MHz
ROESY with presaturation

Current Data Parameters

USER             yilinw
NAME     YW_1_112_8mM_800_25C
EXPNO                 4
PROCNO                1

F1 - Acquisition Parameters
Date_          20130930              Time               0.00
INSTRUM          varian
PROBHD   40:5mmbroadban              PULPROG           roesy              TD                 4096              SOLVENT             D2O              NS                    8              DS                   16
SWH            8797.977 Hz
FIDRES         2.147943 Hz           AQ            0.2328308 sec          RG                  128              DW               56.831 usec         DE                 6.00 usec         TE                298.0 K
ND0                   1              TD                  512              SFO1           799.7986 MHz          FIDRES        17.183548 Hz           SW               11.000 ppm          FnMODE        undefined
NDN              128              TS                  1              MB1              1              LB                 0.00 Hz           GB                    0
ND2              128              MB2              1              LB                 0.00 Hz           GB                    0
ND3              128

F2 - Processing parameters
SI                 2048              SF          799.7947757 MHz          WDW               QSINE
SSB                   2              LB                 0.00 Hz           GB                    0
PC                 1.40

F1 - Processing parameters
SI                 1024              MC2              States              SF          799.7947757 MHz          WDW               QSINE
SSB                   2              LB                 0.00 Hz           GB                    0
PC                 1.40

2D NMR plot parameters
cx2               15.00 cm           cx1               15.00 cm
f2plo            10.000 ppm/cm       f2hzc        8797.957 Hz/cm        f1ppmcm         0.7000 ppm/cm       f1hzc        8799.8568 Hz/cm        f1ppcm     0.7000 ppm/cm       f1ppcm     8799.8568 Hz/cm
HPLC, MS ESI^+ TOF, and NMR (^1H, TOCSY and ROESY) of peptide 2h

Calculated m/z for C_{80}H_{129}N_{23}O_{20}:

- [M+2H]^2+: 867.00
- [M+3H]^3+: 578.33
Thr-H_\text{\alpha}
Orn-H_\text{\alpha}
Leu-H_\text{\alpha}
Val-H_\text{\alpha}
Ile-H_\text{\alpha}
Ala-H_\text{\alpha}
Arg-H_\text{\alpha}
Leu-H_\text{\alpha}
Thr-H_\text{\alpha}
Gln-H_\text{\alpha}
Asn-H_\text{\alpha}
Phe-H_\text{\alpha}
Varian 800MHz TOCSY with water suppression
70ms spinlock mix time

Current Data Parameters

USER             yilinw
NAME     131110_YW_1_QRL
EXPNO                 3
PROCNO                1

F2 - Acquisition Parameters
Date_          20131110             Time               0.00             INSTRUM          varian             PROBHD   ...       287.4             DW               44.656 usec        DE                 6.00 usec        TE                298.0 K

F1 - Acquisition parameters
ND0                   1             TD                  512             SFO1           799.7986 MHz         FIDRES        17.183548 Hz          SW               11.000 ppm         FnMODE        undefined

F2 - Processing parameters
SI                 2048             SF          799.7947714 MHz         WDW               QSINE             SSB                   2             LB                 0.00 Hz          GB                    0             PC                 1.40

F1 - Processing parameters
SI                 1024             MC2              States             SF          799.7947714 MHz         WDW               QSINE             SSB                   2             LB                 0.00 Hz          GB                    0

2D NMR plot parameters
CX2               15.00 cm          CX1               15.00 cm          F2PLO            10.000 ppm         F2LO          ... 0.66670 ppm/cm      F2HZCM        533.22546 Hz/cm       F1PPMCM         0.70113 ppm/cm      F1HZCM        560.75647 Hz/cm
Varian 800MHz
ROESY with presaturation
HPLC, MS ESI^+ TOF, and NMR (^1H, TOCSY and ROESY) of peptide 2i

calculated m/z for C82H134N20O18:

\[ \text{[M+2H]^2+: 844.52} \]
\[ \text{[M+3H]^3+: 563.35} \]

calculated m/z for C_{82}H_{134}N_{20}O_{18}:

\[ \text{[M+2H]^2+: 844.52} \]
\[ \text{[M+3H]^3+: 563.35} \]
Varian 800MHz
TOCSY with water suppression
70ms spinlock mix time

Current Data Parameters
USER             yilinw
NAME     LLA_RM_800_5C             EXPNO                 3             PROCNO                1

F2 - Acquisition Parameters
Date_          20131125             Time               0.00             INSTRUM          varian             PROBHD   ...       287.4             DW               56.831 usec        DE                 6.00 usec        TE                278.0 K

F1 - Acquisition parameters
ND0                   1             TD                  512             SFO1           799.7986 MHz         FIDRES        17.183548 Hz          SW               11.000 ppm         FnMODE        undefined

F2 - Processing parameters
SI                 2048             SF          799.7945677 MHz         WDW               QSINE             SSB                   2             LB                 0.00 Hz          GB                    0             PC                 1.40

F1 - Processing parameters
SI                 1024             MC2              States             SF          799.7945677 MHz         WDW               QSINE             SSB                   2             LB                 0.00 Hz          GB                    0

2D NMR plot parameters
CX2               15.00 cm          CX1               15.00 cm          F2PLO            10.000 ppm         F2LO          ... 0.70002 ppm/cm      F2HZCM        559.86981 Hz/cm       F1PPMCM         0.70002 ppm/cm      F1HZCM        559.86981 Hz/cm
Chapter 3

A Tetramer Derived from Islet Amyloid Polypeptide

Introduction

Interactions among β-sheets are central to the misfolding and aggregation of peptides and proteins that form toxic oligomers and insoluble fibrils in over 40 amyloid diseases, including type 2 diabetes, Alzheimer’s disease, and Parkinson’s disease. The fibrils share the common feature of an extended network of hydrogen-bonded β-sheets that are further stabilized through hydrophobic packing. Less is known about the structures of the smaller, often metastable and polymorphic oligomers, but β-sheets and hydrophobic interactions appear to be important in oligomer formation.

The 37-residue islet amyloid polypeptide (IAPP) aggregates to form fibrils and oligomers that are central to islet β-cell death in the progression of type 2 diabetes. Tycko and coworkers proposed structural models of IAPP fibrils using constraints from solid-state NMR spectroscopy. In these models, a fibril consists of layers of parallel, in-register β-sheets that run perpendicular to the length of the fibril. β-Strands consisting of central residues 8–17 form one of the layers, while β-strands comprising C-terminal residues 28–36 form the other layer. A loop region containing residues 18–27 connects the two β-strands. Using X-ray crystallographic structures derived from fragments of IAPP, Eisenberg and coworkers constructed a similar fibril model in which the side chains are more tightly packed. Langen and coworkers proposed a model of IAPP fibrils using constraints from EPR spectroscopy in which the β-strands pack more loosely. The residues involved in β-sheet formation vary slightly among these different models, but central residues 12–17 and C-terminal residues 31–36 are generally thought to be involved in β-strand formation.
Although the structures of IAPP oligomers are not known at high resolution, they appear to be composed of β-sheets. Through ion mobility-mass spectrometry (IM-MS) studies in conjunction with replica exchange molecular dynamics (REMD), Bowers and coworkers proposed β-hairpin building blocks for human IAPP oligomers.\textsuperscript{26,27} Hoyer and coworkers obtained an NMR-based structure of IAPP in a β-hairpin conformation bound to an affibody and suggested that this β-hairpin might be involved in IAPP aggregation.\textsuperscript{23} The β-hairpin comprises residues 12–28; residues 12–18 and residues 22–28 form β-strands, while residues 19–21 form a turn. In a separate study, Zanni and coworkers used 2D IR spectroscopy to show that residues 23–27 have β-sheet structure in the oligomer but form a disordered loop in the fibril.\textsuperscript{28}

Our laboratory recently introduced macrocyclic β-sheet peptides as a platform to explore the interactions among β-sheets in amyloidogenic peptides and proteins (Figure 3.1).\textsuperscript{28,29} The macrocyclic β-sheet peptides contain a peptide strand and a template strand that are connected by two δ-linked ornithine (δOrn) turn units.\textsuperscript{30,31} The peptide strand contains a heptapeptide sequence derived from an amyloidogenic peptide or protein. The template strand contains four additional α-amino acids and the unnatural amino acid Hao, which mimics a tripeptide β-strand, templates β-sheet formation, and blocks uncontrolled aggregation.\textsuperscript{32} Our laboratory has used macrocyclic β-sheet peptides containing heptapeptide segments from the β-amyloid peptide Aβ, β2-microglobulin, and α-synuclein as inhibitors to control amyloid aggregation and reduce amyloid toxicity.\textsuperscript{29} Recently, Nicholas Truex and I used NMR spectroscopy to study the homotetramers and heterotetramers formed by macrocyclic β-sheet peptides containing residues 17–23 and 30–36 from Aβ.\textsuperscript{33,34}
Figure 3.1. Cartoon representation (top) and chemical structure (bottom) of macrocyclic β-sheet 1. The macrocyclic β-sheet consists of a heptapeptide strand (R₁–R₇) connected by two ornithine turn units to a template strand containing the tripeptide mimic Hao flanked by two α-amino acid residues on each side.

In the current study, I use macrocyclic β-sheet peptides as a platform to explore assembly of the central region of IAPP. I designed peptide 1Arg to contain central residues 11–17 of IAPP (RLANFLV), I chose the IAPP₁₁–₁₇ heptapeptide for its propensity to form a β-strand in fibrils and β-hairpin monomers. I also designed homologue peptide 1Cit, in which I mutated Arg₁₁ to the uncharged isostere of arginine, citrulline (Figure 3.2). Here I describe NMR spectroscopic studies of peptides 1Arg and 1Cit, report the X-ray crystallographic structure of a tetramer formed by a homologue of peptide 1Cit, and correlate the X-ray crystallographic structure with the solution-phase assembly of the IAPP-derived peptides.
Results and Discussion

The β-strand formed by IAPP_{11–17} displays a hydrophobic surface comprising the side chains of Ala_{13}, Phe_{15}, and Val_{17}, as well as Arg_{11}. To reinforce the hydrophobicity of this surface, I incorporated isoleucine residues at positions R_{8} and R_{11} of the template strand. I incorporated lysine residues at positions R_{9} and R_{10} to increase solubility of the peptide and render the surface displaying the side chains of Leu_{12}, Asn_{14}, and Leu_{16} hydrophilic.

In aqueous solution, peptide 1_{Arg} is monomeric. The \textsuperscript{1}H NMR spectrum of peptide 1_{Arg} at 4 mM exhibits a single set of sharp resonances, associated with the monomeric peptide (Figure 3.3 and 3.4). The resonances associated with the α-protons are in the 4–5 ppm range, showing little to no downfield shifting relative to the typical values for the corresponding residues in a random coil conformation (Figure 3.5).\textsuperscript{35} At 8 mM, I observe
broadening of the resonances but no additional peaks associated with assembly of the peptide (Figure 3.3). I hypothesized that the positive charge on Arg11 may prevent peptide 1_{Arg} from oligomerizing. To explore this hypothesis, I replaced Arg_{11} with the neutrally charged isostere citrulline, reducing the net charge from +5 to +4.

**Figure 3.3.** $^1$H NMR spectra of peptide 1_{Arg} at 4 mM and 8 mM and 50 mM CD$_3$COOD and 50 mM CD$_3$COONa buffer in D$_2$O at 500 MHz and 298K.
Figure 3.4. $^1$H NMR spectra of macrocyclic β-sheet peptides $I_{\text{Arg}}$ and $I_{\text{Cit}}$ in 50 mM CD$_3$COOD and 50 mM CD$_3$COONa buffer in D$_2$O at 298 K. The red boxes highlight noteworthy resonances of the tetramer.

Figure 3.5. Downfield shifting of the α-protons of peptide $I_{\text{Arg}}$ at 4 mM relative to those of random coil chemical shifts.*Leucine residues are not assigned in a sequence specific fashion.
Figure 3.6. $^1$H NMR spectra of peptide 1Cit various concentrations and 50 mM CD$_3$COOD and 50 mM CD$_3$COONa buffer in D$_2$O at 500 MHz and 298K.
Peptide $\text{I}_{\text{Cit}}$ is monomeric at low concentrations but forms a tetramer at higher concentrations. At 1 mM, the spectrum is similar to that of peptide $\text{I}_{\text{Arg}}$ (Figure 3.4 and 3.6). At 4 mM, peptide $\text{I}_{\text{Cit}}$ displays two sets of broad resonances associated with the monomer and the tetramer. At 16 mM, only the resonances associated with the tetramer are visible. The resonances associated with the $\alpha$-protons of the tetramer are shifted downfield by up to 1 ppm relative to those of random coil values (Figure 3.7).\textsuperscript{35} This downfield shifting reflects the folding and assembly of the peptide into the tetramer. The aromatic resonances associated with the Phe\textsubscript{15} side chain are shifted upfield by approximately 0.5 ppm, to 6.5 ppm, suggesting that the side chains of Phe\textsubscript{15} pack to form a hydrophobic core within the tetramer.

Comparison of $^1$H NMR spectra of peptide $\text{I}_{\text{Cit}}$ at 1 mM and 16 mM shows that folding accompanies oligomerization. The magnetic anisotropy of the diastereotopic $\delta$-protons of the $^8$Orn turn units reflects $\beta$-sheet folding in macrocyclic $\beta$-sheet peptides.\textsuperscript{30,31} In a well-folded macrocyclic $\beta$-sheet peptide, each diastereotopic pro-$S$ $\delta$-proton resonance is about 0.6 ppm downfield of the corresponding pro-$R$ $\delta$-proton resonance. The monomer subunits of the tetramer formed by peptide $\text{I}_{\text{Cit}}$ are well folded, with the
difference in chemical shifts of the diastereotopic pro-S and pro-R δ-protons being 0.66 and 0.70 ppm. In contrast, monomeric peptide 1Cit is partially folded, with the difference in chemical shifts of the diastereotopic pro-S and pro-R δ-protons being 0.19 and 0.29 ppm.

To further characterize the structure of the tetramer formed by peptide 1Cit, I turned to X-ray crystallography. To facilitate X-ray crystallographic phase determination, I designed and synthesized homologue peptide 2Cit (Figure 3.8). Peptide 2Cit contains the leucine isostere, (2-bromoallyl)glycine, in place of one of the isoleucines in the template strand to allow X-ray crystallographic phase determination by means of single-wavelength anomalous diffraction phasing.13 Peptide 2Cit afforded crystals suitable for X-ray diffraction in conditions containing sodium citrate buffer, isopropanol, and poly(ethylene glycol) (PEG) 4,000.

**Figure 3.8.** Chemical structure of peptide 2Cit with the leucine isostere, (2-bromoallyl)glycine residue in red.

The asymmetric unit contains four folded macrocyclic β-sheets, which pack to form a tetramer. The heptapeptide β-strand of each monomer subunit is hydrogen bonded to the template strand through a network of eight hydrogen bonds (Figure 3.9A). The monomers in the asymmetric unit are similar in conformation with little variation in the
side chains. One notable difference is in the Phe\textsubscript{15} residues, which exhibit two rotamers (Figure 3.9B).

![Figure 3.9](image)

**Figure 3.9.** X-ray crystallographic structure of peptide \(2_{\text{Cit}}\) (PDB 5UHR). (A) Representative monomer subunit. (B) Overlay of the four monomers in the asymmetric unit.

The monomer subunits pair through edge-to-edge hydrogen bonding to form antiparallel \(\beta\)-sheet dimers (Figure 3.10). The two heptapeptide \(\beta\)-strands in the dimer are shifted by two residues towards the C-termini. Six intermolecular hydrogen bonds form between the two monomers. The dimer presents two surfaces. One surface is hydrophobic and displays the side chains of Cit\textsubscript{11}, Ala\textsubscript{13}, Phe\textsubscript{15}, and Val\textsubscript{17} of the peptide strand, as well as the Ile and (2-bromoallyl)glycine of the template strand (Figure 3.10A). The two Phe\textsubscript{15} side chains on the hydrophobic surface adopt different rotamers. The other surface is
hydrophilic and displays the Leu$_{12}$, Asn$_{14}$, and Leu$_{16}$ side chains of the peptide strand, as well as the two Lys residues of the template strand (Figure 3.10B).

![Figure 3.10. X-ray crystallographic structure of the dimer formed by peptide 2cit. (A) View of the hydrophobic surface with side chains shown as spheres. (B) View of the hydrophilic surface with side chains shown as spheres.](image)

Two hydrogen-bonded dimers sandwich together on their hydrophobic surfaces to form a tetramer (Figure 3.11). In the tetramer, the $\beta$-sheets of the dimers are nearly orthogonal. The side chains of Ala$_{13}$, Phe$_{15}$, Val$_{17}$, Ile, and (2-bromoallyl)glycine create a hydrophobic core within the sandwich, with the four phenyl groups packing at the center.
of the sandwich. The two rotamers of the Phe\textsubscript{15} side chains allow the phenyl groups to pack together tightly through hydrophobic interactions and aromatic stacking at the center of the hydrophobic core. The side chains of Ala\textsubscript{13}, Val\textsubscript{17}, Ile, and (2-bromoallyl)glycine surround the four Phe\textsubscript{15} side chains, packing through hydrophobic interaction to stabilize the tetramer. The hydrophilic side chain of Cit\textsubscript{11} extends out of the hydrophobic core. The hydrophilic surfaces of the dimer subunits that comprise the tetramer are exposed to solvent.

*Figure 3.11.* X-ray crystallographic structure of the tetramer of peptide 2\textsubscript{Cit}. (A) Top view. (B) Side view. Sphere representations of Phe\textsubscript{15} show packing of the aromatic side chains in the hydrophobic core.
Diffusion-ordered spectroscopy (DOSY) provides a useful tool for assessing the relative oligomerization state of macrocyclic β-sheets peptides. Oligomers diffuse more slowly than the monomers, with dimers having a diffusion coefficient of about 0.75–0.79 times that of the monomer and tetramers having a diffusion coefficient of about 0.58–0.63 times that of the monomer. At 298 K, the diffusion coefficient of peptide 1Arg is $19.6 \times 10^{-7}$ cm$^2$/s in deuterioacetate buffered D$_2$O (Table 3.1). At 1 mM, peptide 1Cit is monomeric, with a diffusion coefficient of $20.0 \times 10^{-7}$ cm$^2$/s, which is the same as peptide 1Arg within the limits of experimental error. At 2 mM, peptide 1Cit is largely monomeric, with a diffusion coefficient of $18.9 \times 10^{-7}$ cm$^2$/s.

As the concentration is increased and the resonances from the oligomer grow in, the diffusion coefficient of peptide 1Cit decreases. At 4 mM and 8 mM, discrete diffusion coefficients cannot be measured for the resonances associated with the monomer and the oligomer, because exchange occurs at a rate similar to the 75-ms time scale of the experiment. Instead, an averaged diffusion coefficient for the mixture is observed. At 4 mM, the diffusion coefficient is $17.4 \times 10^{-7}$ cm$^2$/s, and at 8 mM the diffusion coefficient is $14.2 \times 10^{-7}$ cm$^2$/s. At 16 mM, the oligomer predominates vastly, and only resonances for the oligomer are observed. At 16 mM, the diffusion coefficient is $12.4 \times 10^{-7}$ cm$^2$/s. This value is about 0.6 times that of the monomer of peptide 1Cit, and is consistent with a tetramer.
Table 3.1. Diffusion coefficients ($D$) of peptides $1_{\text{Arg}}$ and $1_{\text{Cit}}$ in 50 mM CD$_3$COOD and 50 mM CD$_3$COONa buffer in D$_2$O at 298 K.

<table>
<thead>
<tr>
<th>Oligomer state</th>
<th>MW$_{\text{monomer}}$ (Da)</th>
<th>MW$_{\text{tetramer}}$ (Da)</th>
<th>Conc. (mM)</th>
<th>$D$ ($\times 10^{-7}$ cm$^2$/s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>monomer $1_{\text{Arg}}$</td>
<td>1759</td>
<td>7036</td>
<td>4</td>
<td>19.6 ± 0.6</td>
</tr>
<tr>
<td>monomer $1_{\text{Cit}}$</td>
<td>1760</td>
<td>7040</td>
<td>1</td>
<td>20.0 ± 2.0</td>
</tr>
<tr>
<td>monomer $1_{\text{Cit}}$</td>
<td>1760</td>
<td>7040</td>
<td>2</td>
<td>18.9 ± 1.2</td>
</tr>
<tr>
<td>mixture $1_{\text{Cit}}$</td>
<td>1760</td>
<td>7040</td>
<td>4</td>
<td>17.4 ± 1.2</td>
</tr>
<tr>
<td>mixture $1_{\text{Cit}}$</td>
<td>1760</td>
<td>7040</td>
<td>8</td>
<td>14.2 ± 0.3</td>
</tr>
<tr>
<td>tetramer $1_{\text{Cit}}$</td>
<td>1760</td>
<td>7040</td>
<td>16</td>
<td>12.4 ± 0.3</td>
</tr>
</tbody>
</table>

NOESY NMR spectroscopy establishes that the structure of the tetramer formed by peptide $1_{\text{Cit}}$ in aqueous solution is similar to the tetramer observed for peptide $2_{\text{Cit}}$ in the crystal. I observe NOEs from the folding of the monomers and formation of the dimers. Two strong crosspeaks in the NOESY spectrum reflect folding of macrocyclic $\beta$-sheet peptide $1_{\text{Cit}}$, one between the $\alpha$-protons of Leu and Lys, and one between the $\alpha$-proton of Asn$_{14}$ and the proton at the 6-position of the unnatural amino acid Hao (Figure 3.12). NOEs between the $\alpha$-proton and pro-$S$ $\delta$-proton of the $\delta$Orn turn units further reflect folding of the macrocycle. A strong crosspeak between the $\alpha$-protons of Ala$_{13}$ and Val$_{17}$ reflect shifted antiparallel dimer formation. An additional NOE between the methoxy protons of Hao and the Ile side chain reflect packing of the dimers in a sandwich-like fashion (Figure 3.13). The interlayer NOE between the Hao-methoxy and Ile side chain is characteristic of sandwich-like tetramers of Hao-containing macrocyclic $\beta$-sheet peptides.$^{33}$ These NOEs associated with folding, dimerization, and packing reflect the congruence of the X-ray crystallographic and solution-state tetramers.
Figure 3.12. NOEs associated with the dimer subunit of peptide 1Cit. (A) Shifted, antiparallel hydrogen-bonded dimer. Blue arrows indicate intramolecular NOEs and red arrows indicate intermolecular NOE observed in the NOESY spectrum. (B) Expansion of the NOESY spectrum showing selected intramolecular (blue) and intermolecular (red) NOE crosspeaks.
Figure 3.13. NOE associated with the tetramer of peptide $1_{\text{Cit}}$. (A) Green arrow indicates interlayer NOE observed in the NOESY spectrum. (B) NOE crosspeak between the Ile side chain and the methoxy protons of the unnatural amino acid Hao.

To understand why peptide $1_{\text{Cit}}$ forms tetramers but peptide $1_{\text{Arg}}$ does not, I used the X-ray crystallographic structure of peptide $2_{\text{Cit}}$ to generate molecular models of tetramers of peptides $1_{\text{Cit}}$ and $1_{\text{Arg}}$. I modeled the tetramer formed by peptide $1_{\text{Cit}}$ by
mutating the (2-bromoallyl)glycine residue to isoleucine and minimizing the resulting
structure in MacroModel with the MMFFs force field with GB/SA water solvation
(Figure 3.14). I modeled a tetramer of peptide $1_{\text{Arg}}$ in a similar fashion, mutating both the
(2-bromoallyl)glycine and the citrulline residues. Both molecular models overlay well
with the X-ray crystallographic structure of the tetramer of peptide $2_{\text{Cit}}$ (RMSD ~1 Å).
Inspection of the dimer subunits suggests an explanation of the differing stabilities of the
$1_{\text{Cit}}$ and $1_{\text{Arg}}$ tetramers (Figure 3.15). In the dimer subunit of peptide $1_{\text{Arg}}$, the cationic
guanidinium group of each arginine is near the ammonium group of one of the $\delta\text{Orn}$ turn
units, while in the dimer subunit of peptide $1_{\text{Cit}}$, the neutral urea group of citrulline is near
the ammonium group. Thus, it appears that charge-charge repulsion destabilizes the
dimer and hence the tetramer of peptide $1_{\text{Arg}}$. 
Figure 3.14. Crystographically based molecular model of the tetramer formed by peptide $1_{\text{Cr}}$. The model was generated in MacroModel with the MMFFs force field with GB/SA water solvation.
Figure 3.15. Crystallographically based molecular models of the dimer subunits of the tetramers of peptide $1_{\text{Cit}}$ (A) and $1_{\text{Arg}}$ (B). The red boxes highlight interactions between the ammonium groups of the $\delta$Orn turn units and the $\text{Arg}_{11}$ or $\text{Cit}_{11}$ side chains.

The X-ray crystallographic structure and molecular model of the tetramers formed by peptides $2_{\text{Cit}}$ and $1_{\text{Cit}}$ share several features with structures reported for IAPP fibrils. Like the tetramers, the full atomic models of IAPP described by Tycko and coworkers consist of layered $\beta$-sheets in which hydrophobic interactions stabilize the layered structure. In contrast to the tetramers of peptides $2_{\text{Cit}}$ and $1_{\text{Cit}}$, the fibrils consist of parallel $\beta$-sheets formed by IAPP rather than antiparallel $\beta$-sheets. In the two different fibril models proposed by Tycko and coworkers, the Phe$_{15}$ side chains are on either the interior or the exterior of the layers. The fragment-based model of IAPP fibrils proposed by Eisenberg and coworkers also consists of layered parallel $\beta$-sheets, with the side...
chains of Phe$_{15}$ on the exterior of the layers. Recently, Eisenberg and coworkers reported that IAPP$_{15-25}$ forms fibrils consisting of loosely laminated antiparallel $\beta$-sheets.$^{39}$ Hydrophobic interactions of Phe$_{15}$ appear to be more important in the NMR structure of the IAPP $\beta$-hairpin bound to an affibody reported by Hoyer et al., in which the Phe$_{15}$ and Phe$_{23}$ pack tightly against one of the phenylalanine residues in the affibody to form a central core.$^{23}$ This mode of assembly is similar to the packing of Phe$_{15}$ in the tetramers formed by peptides $\textbf{1}_{\text{Cit}}$ and $\textbf{2}_{\text{Cit}}$.

The tetramers formed by peptides $\textbf{1}_{\text{Cit}}$ and $\textbf{2}_{\text{Cit}}$ share common features with assemblies formed by other Hao-containing macrocyclic $\beta$-sheet peptides that our laboratory has studied (Figure 3.16). Several Hao-containing macrocyclic $\beta$-sheet peptides containing heptapeptide sequences from various amyloidogenic peptides and proteins form hydrogen-bonded assemblies laminated through hydrophobic interactions in the crystal state.$^{29,40}$ I have also identified two Hao-containing macrocyclic $\beta$-sheet peptides containing heptapeptide sequences from the $\beta$-amyloid peptide A$\beta$, which assemble to form tetramers in solution.$^{33,34}$ The flat, hydrophobic Hao group appears to facilitate the formation of these layered structures. These structures differ from those that I have observed for N-methylated macrocyclic $\beta$-sheet peptides, which I have also studied (Figure 3.16). Most of the N-methylated macrocyclic $\beta$-sheet peptides containing sequences from various amyloidogenic peptides and proteins that I have observed in the crystal state form compact higher-order oligomers, such as hexamers, octamers, nonamers, and dodecamers.$^{15,16,41,42}$ The N-methylated macrocyclic $\beta$-sheet peptides are generally more twisted than the Hao-containing macrocyclic $\beta$-sheet peptides. This twisting appears to facilitate assembly through interactions between curved hydrophobic
surfaces, in addition to hydrogen bonding. The flat sandwich-like structures formed by the Hao-containing macrocyclic β-sheets resemble the laminated structures of amyloid fibrils, while the compact globular structures formed by the N-methylated macrocyclic β-sheets might offer a glimpse into the structures of amyloid oligomers.

Figure 3.16. Chemical structures of N-methylated macrocyclic β-sheet peptides (top) and Hao-based macrocyclic β-sheet peptides (bottom).

Conclusion

The $^1$H NMR, X-ray crystallographic, and molecular modeling studies of peptides $1_{\text{Arg}}$, $1_{\text{Cit}}$, and $2_{\text{Cit}}$ described above demonstrate the importance of hydrogen bonding and hydrophobic interactions in the oligomerization of IAPP-derived peptides. Peptide $1_{\text{Arg}}$ remains monomeric in aqueous solution, whereas peptides $1_{\text{Cit}}$ and $2_{\text{Cit}}$ assemble to form tetramers in aqueous solution and in the crystal state. The differences between peptides $1_{\text{Arg}}$ and $1_{\text{Cit}}$ suggest that charge-charge interactions can modulate oligomer formation.

Our laboratory has previously used NMR spectroscopy and X-ray crystallography as complimentary techniques to investigate the assembly of different macrocyclic β-sheet peptides derived from Aβ. In these studies, the macrocyclic β-sheet peptides assembled to form tetramers both in solution and in the crystal, but the structure of the
tetramer formed in solution differed from the structure formed in the crystal. The findings of the current paper are significant because they demonstrate that macrocyclic β-sheet peptides can assemble to form the same structure in solution and in the crystal state. Furthermore, the tetramer described here might serve as a structural model for understanding important contacts within oligomers and fibrils formed by full-length IAPP.
References


Material and Methods

Synthesis of Macrocyclic β-Sheet Peptides. Synthesis and purification of the macrocyclic β-sheet peptides were performed as previously described. The peptides were purified by reverse-phase HPLC and the pure fractions were lyophilized to give 22 mg of peptide $1_{\text{Arg}}$, 37 mg of peptide $1_{\text{Cit}}$, and 19 mg of $2_{\text{Cit}}$. Based on resin loading, the yields are 9%, 14%, and 7%, respectively.

Macrocyclic β-Sheet peptide $1_{\text{Arg}}$: HRMS (ESI-TOF) $m/z$: [M + H]$^+$ Calcd for $C_{83}H_{139}N_{24}O_{18}$ 1760.0699; Found 1760.0710.

Macrocyclic β-Sheet peptide $1_{\text{Cit}}$: HRMS (ESI-TOF) $m/z$: [M + Na]$^+$ Calcd for $C_{83}H_{137}N_{23}O_{19}Na$ 1783.0359; Found 1783.0337.

Macrocyclic β-Sheet peptide $2_{\text{Cit}}$: HRMS (ESI-TOF) $m/z$: [M + H]$^+$ Calcd for $C_{82}H_{132}N_{23}O_{19}Br$ 1822.9331; Found 1822.9333.

NMR Spectroscopy of the Macrocyclic β-Sheet Peptides

Sample Preparation. NMR spectroscopy of the macrocyclic β-sheet peptides was performed in $D_2O$ (D, 99.96%; Cambridge Isotope Laboratories, Inc.) with 50 mM $CD_3COOD$ (D, 99.5%; Cambridge Isotope Laboratories, Inc.) and 50 mM $CD_3COONa$ (D, 99%; Cambridge Isotope Laboratories, Inc.). The solutions were prepared by dissolving a weighed portion of the peptide in the appropriate volume of solvent. The molecular weights of the peptides were calculated as the TFA salts with all amino groups assumed to be protonated ($1_{\text{Arg}}$, M.W. 2330.24, $1_{\text{Cit}}$, M.W. 2331.24, and $2_{\text{Cit}}$, M.W. 2394.10). Each solution contained 4,4-dimethyl-4-silapentane-1-ammonium trifluoroacetate (DSA) as an internal standard for referencing chemical shifts. The
solutions were allowed to stand for 24 h to allow complete hydrogen to deuterium exchange of the amide NH protons.

\( ^1 \text{H} \text{NMR, TOCSY, ROESY, and NOESY Data Collection.} \) NMR spectra were recorded on a Bruker 500 MHz spectrometer with a TCI cryoprobe. TOCSY spectra were recorded with 2048 points in the \( f_2 \) dimension and 512 increments in the \( f_1 \) dimension with a 150-ms spin-lock mixing time. TOCSY spectra were recorded with 2048 points in the \( f_2 \) dimension and 512 increments in the \( f_1 \) dimension with either a 100- or 150-ms spin-lock mixing time. NOESY spectra were recorded with 2048 points in the \( f_2 \) dimension and 512 increments in the \( f_1 \) dimension with a 150-ms mixing time.

\( ^1 \text{H} \text{NMR, TOCSY, and NOESY Data Processing.} \) NMR spectra were processed with BrukerXwinNMR software. Automatic baseline correction was applied in both dimensions after phasing the spectra. TOCSY spectra were Fourier transformed to a final matrix size of 4096 x 1024 real points using a Qsine weighting function and forward linear prediction. NOESY and ROESY spectra were Fourier transformed to a final matrix size of 4096 x 2048 real points using a Qsine weighting function and forward linear prediction.

\( \text{Diffusion-Ordered Spectroscopy (DOSY) Experiments.} \) DOSY experiments were performed on a Bruker 500 MHz spectrometer equipped with a TCI cryoprobe, with a diffusion delay (\( \Delta \)) of 75-ms and a diffusion gradient length (\( \delta \)) of 2.5-ms. Sixteen sets of FIDs were recorded with the gradient strength incremented from 5\%–95\% using a linear ramp. The combined FIDs were Fourier transformed in Bruker's TopSpin™ software to give a pseudo-2D spectrum. After phasing and performing baseline correction, each pseudo-2D spectrum was processed with logarithmic scaling on the Y-axis. The Y-axis
was calibrated to the diffusion coefficient of the residual HOD peak in D$_2$O (1.9 x 10$^{-9}$ m$^2$/s at 298 K).$^3$ The diffusion coefficients of the peptides were read and converted from logarithmic values to linear values.

**Crystallization of Peptide 2Cit**

The procedures in this section follow closely to those our laboratory has previously published.$^4$ Initial crystallization conditions for peptide 2Cit were determined using the hanging-drop vapor-diffusion method. Crystallization conditions were screened using three crystallization kits in a 96-well plate format (Hampton Index, PEG/Ion, and Crystal Screen). Three 150 nL hanging drops that differed in the ratio of peptide to well solution were made per condition in each 96-well plate for a total of 864 experiments. Hanging drops were made by combining an appropriate volume of peptide 2Cit (10 mg/mL in deionized water) with an appropriate volume of well solution to create three 150-nL hanging drops with 1:1, 1:2, and 2:1 peptide:well solution. The hanging drops were made using a TTP LabTech Mosquito nanodisperse instrument. Crystals of peptide 2Cit grew in ~48 h in a solution of 0.1 M sodium citrate at pH 5.0, 20% (v/v) isopropanol, and 18% PEG 4000.

Crystallization conditions for peptide 2Cit were optimized using a 4x6 matrix Hampton VDX 24-well plate. The sodium citrate pH was varied in each row in increments of 0.5 pH units (4.0, 4.5, 5.0, and 5.5) and the isopropanol concentration in each column in increments of 2% (26%, 24%, 22%, 20%, 18%, 16%). The first well in the 4x6 matrix was prepared by combined 100 µL of 1 M sodium citrate at pH 4.0, 260 µL of isopropanol, 360 µL of 50% (w/v) PEG 4000, and 280 µL of deionized water. The
other wells were prepared in analogous fashion, by combining 100 µL of sodium citrate of varying pH, 360 µL of 50% (w/v) PEG 4000, isopropanol in varying amounts, and deionized water for a total volume of 1 mL in each well.

Three hanging-drops were prepared per borosilicate glass slide by combining a solution of peptide $2_{\text{Cit}}$ (10 mg/mL in deionized water) and the well solution in the following amounts: 1 µL:1 µL, 2 µL:1 µL, and 1 µL:2 µL. Slides were inverted and pressed firmly against the silicone grease surrounding each well. Crystals of peptide $2_{\text{Cit}}$ suitable for X-ray diffraction grew in ~3 days. Crystallization conditions were further optimized using smaller variations in sodium citrate pH (in increments of 0.2 pH units) and isopropanol concentrations (in increments of 1%). Crystals were harvested with a nylon loop attached to a copper or steel pin and flash frozen in liquid nitrogen prior to data collection. The optimized crystallization conditions for peptide $2_{\text{Cit}}$ are summarized in the supplementary information.

Diffraction data for peptide $2_{\text{Cit}}$ were collected at the Stanford Synchrotron Radiation Lightsource (SSRL) with a synchrotron source at 0.92-Å wavelength. Diffraction data were scaled and merged using XDS. Coordinates for the anomalous signal were determined by HySS in the Phenix software suite 1.10.1. The electron density map was generated in Phaser using the coordinates of the bromine anomalous signal. Molecular manipulation of the model was performed with Coot. Coordinates were refined with phenix.refine.

**Molecular Modeling of the Macroyclic β-Sheet Peptides**

Molecular models of the tetramers of peptides $1_{\text{Arg}}$ and $1_{\text{Cit}}$ were generated from the X-ray crystallographic structure of the homologous peptide $2_{\text{Cit}}$ (PDB: 5UHR). 1
modeled the tetramer formed by peptides 1Cit by mutating the (2-bromoallyl)glycine residue to isoleucine and the side chain torsion angles were adjusted to match the resulting NOE. I modeled a tetramer of peptide 1Arg in a similar fashion, mutating both the (2-bromoallyl)glycine and the citrulline residues. The coordinates were exported from PyMOL and the file was imported into MacroModel with the Maestro user interface. Atom types and bond orders were edited as needed to correct errors in bond type and charge. Minimization was performed with the MMFFs force field and GB/SA water solvation.
References


**RP-HPLC of Macrocyclic β-Sheet 1Arg**

<table>
<thead>
<tr>
<th>Peak</th>
<th>RetTime</th>
<th>Type</th>
<th>Width</th>
<th>Area</th>
<th>Height</th>
<th>Area</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>8.629</td>
<td>MF</td>
<td>0.1768</td>
<td>685.6629</td>
<td>64.6265</td>
<td>10.0330</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>8.799</td>
<td>FM</td>
<td>0.0584</td>
<td>6148.4335</td>
<td>1756.0099</td>
<td>89.9670</td>
<td></td>
</tr>
</tbody>
</table>

**MS (ESI) of Macrocyclic β-Sheet 1Arg**

Calculated m/z for C_{83}H_{138}N_{24}O_{18}:

- [M+H]^+: 1760.07
- [M+2H]^2+: 880.54
- [M+3H]^3+: 587.36

**Columns**

- Aeris XB-C18 2.6μ, 150 mm x 4.6 mm

**Mobile Phase**

- A: H2O, 0.1% TFA
- B: CH3CN, 0.1% TFA

**Gradient**

- A/B (95:5) to (0:100) in 20 min

**Flow Rate**

- 1.0 mL/min

**Detection**

- VWD, wavelength = 214 nm

**Temperature**

- 298 K
$^1$H NMR of macrocyclic $\beta$-sheet peptide $1_{\text{Arg}}$, 4 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR of macrocyclic β-sheet peptide 1Arg, 4 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR of macrocyclic $\beta$-sheet peptide 1$_{\text{Arg}}$, 4 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR of macrocyclic β-sheet peptide 1$_{\text{Arg}}$, 4 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR of macrocyclic β-sheet peptide $^1$Arg, 4 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
\(^1\)H NMR 2D TOCSY of macrocyclic \(\beta\)-sheet peptide \(1_{\text{Arg}}\) with 150-ms spin-lock mixing time
4 mM in 100 mM deuterioacetate buffer in D\(_2\)O at 500 MHz and 298 K
$^1$H NMR 2D TOCSY of macrocyclic $\beta$-sheet peptide $1_{\text{Arg}}$ with 150-ms spin-lock mixing time
4 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR 2D ROESY of macrocyclic $\beta$-sheet peptide 1Arg with 150-ms spin-lock mixing time
4 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR 2D ROESY of macrocyclic β-sheet peptide 1Arg with 150-ms spin-lock mixing time
4 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR DOSY of macrocyclic $\beta$-sheet peptide $1_{\text{Arg}}$ at 500 MHz and 298 K
4 mM in 100 mM deuterioacetate buffer in D$_2$O

Calculations for macrocyclic $\beta$-sheet peptide $1_{\text{Arg}}$ at 4 mM

$D_{\text{HOD}} = 19.0 \times 10^{-10} \text{ m}^2/\text{s}$

$log \ (D_{\text{HOD}}) = -8.721$

$D_{\text{monomer}}: \ log(D) = -9.708; \ D = 10^{-9.708} = 19.6 \pm 0.6 \times 10^{-11} \text{ m}^2/\text{s}$

### RP-HPLC of Macroyclic β-Sheet 1\text{Citr}

**Column:** Aeris XB-C18 2.6μ

**Dimensions:** 150 mm x 4.6 mm

**Mobile Phase:**
- A: H$_2$O, 0.1% TFA
- B: CH$_3$CN, 0.1% TFA

**Gradient:** A:B (95:5) to (0:100) in 20 min

**Flow Rate:** 1.0 mL/min

**Detection:** VWD, wavelength = 214 nm

**Temperature:** 298 K

### MS (ESI) of Macroyclic β-Sheet 1\text{Citr}

#### Calculated m/z for C$_{83}$H$_{137}$N$_{23}$O$_{19}$:

- [M+H]$^+$: 1761.06
- [M+2H]$^{2+}$: 881.03
- [M+3H]$^{3+}$: 587.69

#### Chromatogram

<table>
<thead>
<tr>
<th>Peak</th>
<th>Ret Time</th>
<th>Type</th>
<th>Width</th>
<th>Area</th>
<th>Height</th>
<th>Area</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>8.758</td>
<td>MF</td>
<td>0.0983</td>
<td>1323.3335</td>
<td>224.3247</td>
<td>2.2091</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>9.374</td>
<td>FM</td>
<td>0.2858</td>
<td>5.4981e4</td>
<td>3206.0356</td>
<td>91.7819</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>9.738</td>
<td>FM</td>
<td>0.1130</td>
<td>3999.7199</td>
<td>530.8340</td>
<td>6.0090</td>
<td></td>
</tr>
</tbody>
</table>

#### Mass Spectrum

**[M+H]$^+$** spectrum with peaks at 1761.06, 881.03, and 587.69.
\(^1H\) NMR of macrocyclic \(\beta\)-sheet peptide 1\(\text{Cit}\) \(2\) mM in \(100\) mM deuterioacetate buffer in \(D_2O\) at \(500\) MHz and \(298\) K

![NMR spectrum](image-url)

---

**Current Data Parameters**

**USER** yilinw  
**NAME** 20170207_YW_citLANFLV-IKHAOKI-2mM_dosynoesu  
**EXPNO** 1  
**PROCNO** 1  

**F2 - Acquisition Parameters**

- **Date** 20170208  
- **Time** 21.38  
- **INSTRUM** cryo500  
- **PROBHD** 5 mm CPTCI 1H-  
- **PULPROG** zg30  
- **TD** 81728  
- **SOLVENT** D2ONS 256  
- **DS** 2  
- **SWH** 8012.820 Hz  
- **FIDRES** 0.098043 Hz  
- **Q** 5.0998774 sec  
- **RG** 71.8  
- **DW** 62.400 usec  
- **DE** 6.00 usec  
- **TE** 298.0 K  
- **D1** 0.10000000 sec  
- **MCREST** 0.00000000 sec  
- **MCWRK** 0.01500000 sec  

**F2 - Processing parameters**

- **SI** 65536  
- **SF** 500.2200207 MHz  
- **WDW** EM  
- **SSB** 0  
- **LB** 0.30 Hz  
- **GB** 0  
- **PC** 1.00  

**1D NMR plot parameters**

- **CX** 22.80 cm  
- **CY** 10.00 cm  
- **F1P** 10.000 ppm  
- **F1** 500.22 Hz  
- **F2P** -0.100 ppm  
- **F2** -50.02 Hz  

**PPMCM** 0.44298 ppm/cm  
**HZCM** 221.58871 Hz/cm
\(^1\)H NMR of macrocyclic \(\beta\)-sheet peptide 1\textsubscript{Cit}, 2 mM in 100 mM deuterioacetate buffer in D\(_2\)O at 500 MHz and 298 K
1H NMR of macrocyclic β-sheet peptide 1_Cit, 2 mM in 100 mM deuterioacetate buffer in D2O at 500 MHz and 298 K
$^1$H NMR of macrocyclic $\beta$-sheet peptide $1_{\text{Cit}}$, 2 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR of macrocyclic $\beta$-sheet peptide 1Cit, 2 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR 2D TOCSY of macrocyclic β-sheet peptide 1Cit with 150-ms spin-lock mixing time
2 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR 2D TOCSY of macrocyclic $\beta$-sheet peptide 1Cit with 150-ms spin-lock mixing time

2 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR 2D ROESY of macrocyclic $\beta$-sheet peptide $\text{1Cit}$ with 100-ms spin-lock mixing time
2 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
\(^1\)H NMR 2D ROESY of macrocyclic β-sheet peptide 1Cit with 100-ms spin-lock mixing time
2 mM in 100 mM deuterioacetate buffer in D\(_2\)O at 500 MHz and 298 K
$^1$H NMR of macrocyclic β-sheet peptide 1Cit, 16 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K

Chemical shift values for 1Cit are shown in the spectrum. The compound is dissolved in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K.
1H NMR of macrocyclic β-sheet peptide 1Cit, 16 mM in 100 mM deuterioacetate buffer in D₂O at 500 MHz and 298 K
$^1$H NMR of macrocyclic $\beta$-sheet peptide $1_{\text{Cit}}$, 16 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR of macrocyclic β-sheet peptide $1_{\text{Cit}}$, 16 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR of macrocyclic $\beta$-sheet peptide 1Cit, 16 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR of macrocyclic β-sheet peptide $1_{\text{Cit}}$. 16 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR 2D TOCSY of macrocyclic β-sheet peptide 1Cit with 150-ms spin-lock mixing time
16 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR 2D TOCSY of macrocyclic β-sheet peptide $1_{Cit}$ with 150-ms spin-lock mixing time
16 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR 2D TOCSY of macrocyclic β-sheet peptide $1_{\text{Cit}}$ with 150-ms spin-lock mixing time
16 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR 2D TOCSY of macrocyclic β-sheet peptide 1Cit
16 mM in D$_2$O at 500 MHz and 298 K with 150-ms spin-lock mixing time
$^1$H NMR 2D NOESY of macrocyclic β-sheet peptide 1Cit with 150-ms mixing time
16 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR 2D NOESY of macrocyclic β-sheet peptide 1Cit with 150-ms mixing time
16 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR 2D NOESY of macrocyclic $\beta$-sheet peptide 1Cit with 150-ms mixing time
16 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR 2D NOESY of macrocyclic $\beta$-sheet peptide $1_{\text{Cit}}$ with 150-ms mixing time
16 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
1H NMR DOSY of macrocyclic β-sheet peptide 1Cit at 500 MHz and 298 K
1 mM in 100 mM deuterioacetate buffer in D₂O

Calculations for macrocyclic β-sheet peptide 1Cit at 1 mM

\[ D_{\text{HOD}} = 19.0 \times 10^{-10} \text{ m}^2/\text{s} \]
\[ \log(D_{\text{HOD}}) = -8.721 \]

\[ D_{\text{monomer}} : \log(D) = -9.700; D = 10^{-9.700} = 20.0 \pm 2.0 \times 10^{-11} \text{ m}^2/\text{s} \]

$^1$H NMR DOSY of macrocyclic $\beta$-sheet peptide 1Cit at 500 MHz and 298 K
2 mM in 100 mM deuterioacetate buffer in D$_2$O

Calculations for macrocyclic $\beta$-sheet peptide 1Cit at 2 mM

$D_{\text{HOD}} = 19.0 \times 10^{-10}$ m$^2$/s $^a$

$\log(D_{\text{HOD}}) = -8.721$

$D_{\text{monomer}}: \log(D) = -9.723; D = 10^{-9.723} = 18.9 \pm 1.2 \times 10^{-11}$ m$^2$/s

1H NMR DOSY of macrocyclic β-sheet peptide 1Cit at 500 MHz and 298 K
4 mM in 100 mM deuterioacetate buffer in D2O

Calculations for macrocyclic β-sheet peptide 1Cit at 4 mM

\[ D_{HOD} = 19.0 \times 10^{-10} \text{ m}^2/\text{s} \]
\[ \log (D_{HOD}) = -8.721 \]

\[ D_{\text{monomer}}: \log(D) = -9.759; D = 10^{-9.759} = 17.4 \pm 1.2 \times 10^{-11} \text{ m}^2/\text{s} \]

\[ a \text{Longworth, L. G. J. Phys. Chem. 1960, 64, 1914–1917.} \]
$^1$H NMR DOSY of macrocyclic $\beta$-sheet peptide $1_{\text{Cit}}$ at 500 MHz and 298 K
8 mM in 100 mM deuterioacetate buffer in D$_2$O

Calculations for macrocyclic $\beta$-sheet peptide $1_{\text{Cit}}$ at 8 mM

$D_{\text{HOD}} = 19.0 \times 10^{-10}$ m$^2$/s $^a$

$\log (D_{\text{HOD}}) = -8.721$

$D_{\text{monomer}}: \log(D) = -9.849; D = 10^{-9.849} = 14.2 \pm 0.3 \times 10^{-11}$ m$^2$/s

$^1$H NMR DOSY of macrocyclic β-sheet peptide $1_{\text{Cit}}$ at 500 MHz and 298 K
16 mM in 100 mM deuterioacetate buffer in D$_2$O

Calculations for macrocyclic β-sheet peptide $1_{\text{Cit}}$ at 16 mM

$D_{\text{HOD}} = 19.0 \times 10^{-10}$ m$^2$/s $^a$

$\log(D_{\text{HOD}}) = -8.721$

$D_{\text{monomer}}: \log(D) = -9.905; D = 10^{-9.905} = 12.4 \pm 0.3 \times 10^{-11}$ m$^2$/s

MS (ESI) of Macrocyclic β-Sheet 2Cit

calculated m/z for C₈₂H₁₃₂N₂₃O₁₉Br:

- [M+H]^+: 1822.93
- [M+2H]^2+: 911.97
- [M+3H]^3+: 608.31
$^1$H NMR of macrocyclic β-sheet peptide 2Cit, 1 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
1H NMR of macrocyclic β-sheet peptide 2Cit, 1 mM in 100 mM deuterioacetate buffer in D2O at 500 MHz and 298 K

<table>
<thead>
<tr>
<th>ppm</th>
<th>7.0</th>
<th>7.2</th>
<th>7.4</th>
<th>7.6</th>
<th>7.8</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.9342</td>
<td>0.8478</td>
<td>1.0668</td>
<td>2.9624</td>
<td>1.8567</td>
<td></td>
</tr>
</tbody>
</table>
\(^1\)H NMR of macrocyclic \(\beta\)-sheet peptide 2Cit, 1 mM in 100 mM deuterioacetate buffer in D\(_2\)O at 500 MHz and 298 K
\(^1\)H NMR of macrocyclic \(\beta\)-sheet peptide \(2_{\text{Cit}}\), 1 mM in 100 mM deuterioacetate buffer in \(\text{D}_2\text{O}\) at 500 MHz and 298 K
$^1$H NMR of macrocyclic β-sheet peptide $2_{\text{Cit}}$, 1 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
Chapter 4

Effects of Charge and Hydrophobicity on the Oligomerization of a Peptide Derived from IAPP
Introduction

pH provides a critical trigger for changes in protein conformation and structure. Decreases in pH trigger the release of oxygen from hemoglobin in the bloodstream to tissues where it is needed.¹ The cooperative protonation of histidine residues in the hemoglobin tetramer provide the trigger mechanism.²,³ Decreases in pH also trigger fusion of the endosomal and viral membranes in the transmission of influenza A viruses. This process occurs through the protonation of histidine residues in influenza hemagglutinin, which causes refolding and binding to receptors on the host cells, which then induce endocytosis of the virus.⁴-⁶ Researchers have also exploited variations in pH for drug delivery to environments where there are subtle pH changes.⁷-¹¹ Polyhistidine-based micelles were designed to respond to acidic tumour microenvironments and a copolymer nanoparticle incorporating a polyhistidine sequence was designed to increase uptake of antibiotic through acidic bacterial cell walls.⁷,⁸ pH can also provide a conformational switch in the folding of synthetic macromolecules.¹²-¹⁴ In a recent study, Andersen and coworkers designed a pH switch for β-sheet folding in which the hexapeptide sequence HPATGK switches from unstructured to a turn at physiological and higher pH.¹³ Histidine residues provide a good trigger for these biological and biomimetic processes because its protonation state changes near physiological pH.

In the current study, I set out to explore the role of charge and hydrophobicity in peptide self-assembly and ask whether pH can modulate assembly. I performed these studies with a well-characterized peptide model system that assembles to form tetramers in both aqueous solution and in the crystal state.¹⁵,¹⁶ The model system consists of macrocyclic β-sheet peptides containing residues 11–17 of the islet amyloid polypeptide (IAPP). Peptides ¹Arg and ¹Cit (Figure 4.2), which I had previously characterized, are representative of the model system. Peptide ¹Arg
consists of a peptide strand and a template strand that are connected by two δ-linked ornithine (Orn) turn units.\textsuperscript{17,18} The peptide strand of 1Arg contains the IAPP\textsubscript{11–17} heptapeptide sequence RLANFLV, and the template strand contains isoleucine and lysine residues to reinforce hydrophobicity and increase solubility respectively. The unnatural amino acid Hao is centered within the template strand and mimics a tripeptide β-strand, templates β-sheet formation, and blocks uncontrolled aggregation.\textsuperscript{19} Peptide 1Cit is a homologue, in which cationic Arg\textsubscript{11} is replaced by the neutral isostere citrulline. Citrulline contains a urea group in place of the guanidinium group. Peptide 1Cit assembles to form tetramers at low millimolar concentrations in aqueous solution (Figure 4.1), whereas Peptide 1Arg is monomeric under these conditions.

\textbf{Figure 4.1.} Tetramer formation of peptide 1Cit. X-ray crystallographic structure of the tetramer and of the monomer subunit of a heavy atom derivative of peptide 1Cit (PDB 5UHR). The tetramer consists of a sandwich of hydrogen-bonded dimers laminated through hydrophobic interactions.

Inspired by my previous results and by the role of pH in protein interactions, I further explored the role of charge and hydrophobicity in the assembly of macrocyclic β-sheet peptides derived from IAPP\textsubscript{11–17}. I incorporated glutamic acid at position 11 to create peptide 1Glu, and leucine at position 11 to create peptide 1Leu, and I studied the assembly of the peptides by NMR spectroscopy (Figure 4.2). My efforts culminated in peptide 1His, a macrocyclic β-sheet peptide that changes oligomerization state in response to pH.

156
Figure 4.2. Chemical structure of macrocyclic β-sheet peptides peptides $1\text{Arg}$, $1\text{Cit}$, $1\text{Glu}$, $1\text{Leu}$, and $1\text{His}$ with different residues at position 11.

**Results and Discussion**

The $^1$H NMR spectrum of macrocyclic β-sheet peptides reflects their oligomerization state.\textsuperscript{15,16,20-22} In the monomeric state, resonances are sharp and are generally at values typical of the corresponding random coil amino acids.\textsuperscript{23} In the tetrameric state, resonances are often broader, the resonances of the α-protons are generally shifted downfield and the aromatic resonances are often shifted upfield.

In aqueous solution at 298 K, $^1$H NMR spectrum of peptide $1\text{Arg}$ at 4 mM displays a single set of sharp resonances, indicating that the peptide is monomeric (Figure 4.3). The resonances associated with the α-protons are upfield of the HOD peak at around 4–5 ppm and the resonances associated with the Phe$_{15}$ side chain are at around 7 ppm, showing little to no shifting relative to the typical values for the corresponding residues in a random coil confirmation.\textsuperscript{23} At 8 mM, the $^1$H NMR spectrum of peptide $1\text{Arg}$ shows broadening of the resonances but no additional peaks associated with the onset of peptide self association. $^1$H NMR spectrum of peptide $1\text{Cit}$ at 1 mM resembles the $^1$H spectrum of peptide $1\text{Arg}$ and displays a single set of sharp resonances, indicating that the peptide is monomeric. At 4 mM, peptide $1\text{Cit}$ displays two sets of broad
resonances associated with the monomer and the tetramer, and at 16 mM only the resonances associated with the tetramer are visible. The tetramer resonances associated with the \(\alpha\)-protons are shifted downfield by up to 1 ppm relative to those of random coil \(\alpha\)-protons. The aromatic resonances associated with the Phe\(_{15}\) side chain are shifted upfield from 7.0 to 6.5 ppm. The shifting of the resonances reflects the folding and assembly of the peptide into a tetramer.

**Figure 4.3.** \(^1\)H NMR spectra of macrocyclic \(\beta\)-sheet peptides \(1_{\text{Arg}}\), \(1_{\text{Cit}}\), \(1_{\text{Glu}}\), and \(1_{\text{Leu}}\) in 50 mM CD\(_3\)COOD and 50 mM CD\(_3\)COONa buffer in D\(_2\)O at 298 K. The red boxes highlight key resonances in the tetramer.

The magnetic anisotropy of the diastereotopic \(\delta\)-protons of the \(\delta\)Orn turn units reflects \(\beta\)-sheet folding in macrocyclic \(\beta\)-sheet peptides.\(^{18}\) Previous studies in our laboratory have shown that complete folding accompanies oligomerization.\(^{15,20,21}\) In a well-folded macrocyclic \(\beta\)-sheet peptide, each diastereotopic \(\text{pro-S}\) \(\delta\)-proton resonance is about 0.6 ppm downfield of the corresponding \(\text{pro-R}\) \(\delta\)-proton resonance. The \(^1\)H NMR spectrum of monomeric peptide \(1_{\text{Arg}}\) shows that it is partially folded, with average difference in chemical shifts being 0.31 ppm. In contrast, the monomer subunits of the tetramer formed by peptides \(1_{\text{Cit}}\), \(1_{\text{Glu}}\), and \(1_{\text{Leu}}\) are well folded with average differences in chemical shifts being 0.68, 0.64, 0.66 ppm, respectively (Table 4.1).
Table 4.1. $\Delta\delta^8$Orn values of peptides $\mathbf{1}_{\text{Arg}}$, $\mathbf{1}_{\text{Cit}}$, $\mathbf{1}_{\text{Glu}}$, $\mathbf{1}_{\text{Leu}}$, $\mathbf{1}_{\text{His}}$ in D$_2$O at 298 K.

<table>
<thead>
<tr>
<th></th>
<th>pH</th>
<th>Conc (mM)</th>
<th>$\Delta\delta^8$Orn (ppm)</th>
<th>$\Delta\delta^8$Orn (ppm)</th>
<th>average $\Delta\delta^8$Orn (ppm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>$\mathbf{1}_{\text{Arg}}$</td>
<td>4.7$^a$</td>
<td>4</td>
<td>0.31</td>
<td>0.31</td>
<td>0.31</td>
</tr>
<tr>
<td>$\mathbf{1}_{\text{Cit}}$</td>
<td>4.7$^a$</td>
<td>16</td>
<td>0.70</td>
<td>0.66</td>
<td>0.68</td>
</tr>
<tr>
<td>$\mathbf{1}_{\text{Glu}}$</td>
<td>4.7$^a$</td>
<td>16</td>
<td>0.69</td>
<td>0.59</td>
<td>0.64</td>
</tr>
<tr>
<td>$\mathbf{1}_{\text{Leu}}$</td>
<td>4.7$^a$</td>
<td>16</td>
<td>0.71</td>
<td>0.60</td>
<td>0.66</td>
</tr>
<tr>
<td>$\mathbf{1}_{\text{His}}$</td>
<td>2.5$^b$</td>
<td>1</td>
<td>0.29</td>
<td>0.29</td>
<td>0.29</td>
</tr>
<tr>
<td>$\mathbf{1}_{\text{His}}$</td>
<td>2.5$^b$</td>
<td>16</td>
<td>0.47</td>
<td>0.47</td>
<td>0.47</td>
</tr>
<tr>
<td>$\mathbf{1}_{\text{His}}$</td>
<td>4.7$^a$</td>
<td>16</td>
<td>0.51</td>
<td>0.51</td>
<td>0.51</td>
</tr>
<tr>
<td>$\mathbf{1}_{\text{His}}$</td>
<td>7.2$^c$</td>
<td>16</td>
<td>0.57</td>
<td>0.77</td>
<td>0.67</td>
</tr>
</tbody>
</table>

$^a$50 mM CD$_3$COOD and 50 mM CD$_3$COONa buffered D$_2$O.
$^b$Unbuffered peptide in D$_2$O.
$^c$50 mM CD$_3$COOD and 50 mM CD$_3$COONa buffered D$_2$O with the pH adjusted to 7.2 with NaOD.

To better understand how charge and hydrophobicity affect oligomerization, I compared homologues $\mathbf{1}_{\text{Cit}}$, $\mathbf{1}_{\text{Glu}}$, and $\mathbf{1}_{\text{Leu}}$ and evaluated the effects of the respective polar, acidic, and hydrophobic residues at position 11. Peptides $\mathbf{1}_{\text{Cit}}$, $\mathbf{1}_{\text{Glu}}$, and $\mathbf{1}_{\text{Leu}}$ are monomeric at submillimolar concentrations in aqueous solution, but form tetramers at millimolar concentrations (Figure 4.5 and 4.6). The $^1$H NMR spectra of peptides $\mathbf{1}_{\text{Cit}}$, $\mathbf{1}_{\text{Glu}}$, and $\mathbf{1}_{\text{Leu}}$ show only single sets of sharp resonances associated with the monomer at 0.1 mM. The chemical shifts of the $\alpha$-proton and aromatic resonances are similar to those of peptide $\mathbf{1}_{\text{Arg}}$, reflecting the monomeric state of the peptides at low concentrations (Figure 4.3). At 8 mM, each of the three peptides display two sets of resonances, which correspond to the monomer and the tetramer (Figure 4.2, 4.5, and 4.6). The $^1$H NMR spectra of the three peptides are broad, and key resonances appear at similar positions, with the $\alpha$-proton resonances of the tetramers being shifted downfield and the aromatic resonances shifted upfield.

To assess the propensities of peptides $\mathbf{1}_{\text{Cit}}$, $\mathbf{1}_{\text{Glu}}$, and $\mathbf{1}_{\text{Leu}}$ to form tetramers, I measured the monomer–tetramer ratios at 1, 2, 4, and 8 mM by $^1$H NMR spectroscopy. Integration of the Hao$_6$
and Hao₄ resonances permits the measurement of the monomer and the tetramer ratio (Figure 4.4). Peptide 1_Cit is about 50% tetrameric at 4 mM, peptide 1_Glu is 50% tetrameric at 2 mM, and peptide 1_Leu is 50% tetrameric at just above 1 mM. These studies show the following propensities for these peptides to form tetramers: 1_Leu > 1_Glu > 1_Cit >> 1_Arg.

![Graph showing the percentage of tetrameric peptides 1_Cit, 1_Glu, and 1_Leu at 1, 2, 4, and 8 mM. The values are derived from integrations of the Hao₄ and Hao₆ resonances of the tetramer and the monomer.](image)

**Figure 4.4.** Percentage of tetrameric peptides 1_Cit, 1_Glu, and 1_Leu at 1, 2, 4, and 8 mM. The values are derived from integrations of the Hao₄ and Hao₆ resonances of the tetramer and the monomer.
Figure 4.5. $^1$H NMR spectra of peptide $1_{\text{Glu}}$ various concentrations and 50 mM CD$_3$COOD and 50 mM CD$_3$COONa buffer in D$_2$O at 500 MHz and 298K.
Figure 4.6. $^1$H NMR spectra of peptide 1Gly various concentrations and 50 mM CD$_3$COOD and 50 mM CD$_3$COONa buffer in D$_2$O at 500 MHz and 298K.
Electrostatic and hydrophobic interactions explain the relative propensities of peptides 1Cit, 1Glu, 1Leu, and 1Arg to form tetramers in aqueous solution. I previously observed that a derivative of peptide 1Cit containing a heavy atom forms sandwich-like tetramers (Figure 4.1). The crystallographic structure (PDB 5UHR) shows the side chain of Cit11 is proximal to the protonated α-amine of Orn in the dimer subunits of the tetramer. This interaction is crucial to the propensity of tetramer formation. Peptide 1Leu has the highest propensity to oligomerize as it has a non-polar residue at position 11, which can further contribute to the hydrophobic core. Peptide 1Glu has the second highest propensity to oligomerize as it has a negatively charged, polar residue at position 11, which allows for electrostatic attraction or the formation of a salt bridge with the α-amine of δOrn. Peptide 1Cit has the lowest propensity to oligomerize as it has a polar, neutral side chain. In contrast, peptide 1Arg does not oligomerize as the electrostatic repulsion of the positively charged side chain of Arg11 and the protonated α-amine of δOrn inhibits the formation of the dimer.

Diffusion-ordered spectroscopy (DOSY) provides a convenient method to assess the relative oligomerization state of macrocyclic β-sheet peptides 1. Dimers typically have a diffusion coefficient of about 0.75–0.79 times that of monomers, and tetramers have a diffusion coefficient of about 0.58–0.63 times that of monomers.\textsuperscript{15,16,20,24,25} We have previously observed that monomers exhibit a diffusion coefficient of about $20 \times 10^{-7}$ cm\textsuperscript{2}/s, while tetramers exhibit a diffusion coefficient of about $12 \times 10^{-7}$ cm\textsuperscript{2}/s in deuterioacetate buffered D\textsubscript{2}O at 298 K. At 16 mM, diffusion coefficient of peptides 1Glu and 1Leu are consistent with that of tetramers. In deuterioacetate buffer at pH 4.7 and 7.2, the diffusion coefficient of peptide 1Glu are 12.1 and $12.4 \times 10^{-7}$ cm\textsuperscript{2}/s, respectively (Table 4.2). At pH 4.7 and 7.2 in deuterioacetate buffer, the diffusion coefficient of peptide 1Leu are 11.4 and $12.3 \times 10^{-7}$ cm\textsuperscript{2}/s, respectively.
Table 4.2. Diffusion coefficients ($D$) of peptides $\mathbf{1}_{\text{Glu}}, \mathbf{1}_{\text{Leu}}, \mathbf{1}_{\text{His}}$ in D$_2$O at 298 K.

<table>
<thead>
<tr>
<th>conc (mM)</th>
<th>pH</th>
<th>$D$ ($10^{-7}$ cm$^2$/s)</th>
<th>oligomer state</th>
</tr>
</thead>
<tbody>
<tr>
<td>$\mathbf{1}_{\text{Glu}}$</td>
<td>16</td>
<td>4.7&lt;sup&gt;a&lt;/sup&gt;</td>
<td>12.1 ± 0.6</td>
</tr>
<tr>
<td>$\mathbf{1}_{\text{Glu}}$</td>
<td>16</td>
<td>7.2&lt;sup&gt;c&lt;/sup&gt;</td>
<td>12.4 ± 0.3</td>
</tr>
<tr>
<td>$\mathbf{1}_{\text{Leu}}$</td>
<td>16</td>
<td>4.7&lt;sup&gt;a&lt;/sup&gt;</td>
<td>11.4 ± 0.5</td>
</tr>
<tr>
<td>$\mathbf{1}_{\text{Leu}}$</td>
<td>16</td>
<td>7.2&lt;sup&gt;c&lt;/sup&gt;</td>
<td>12.3 ± 1.3</td>
</tr>
<tr>
<td>$\mathbf{1}_{\text{His}}$</td>
<td>1</td>
<td>2.5&lt;sup&gt;b&lt;/sup&gt;</td>
<td>19.8 ± 0.8</td>
</tr>
<tr>
<td>$\mathbf{1}_{\text{His}}$</td>
<td>4</td>
<td>2.5&lt;sup&gt;b&lt;/sup&gt;</td>
<td>16.8 ± 0.6</td>
</tr>
<tr>
<td>$\mathbf{1}_{\text{His}}$</td>
<td>8</td>
<td>2.5&lt;sup&gt;b&lt;/sup&gt;</td>
<td>16.4 ± 0.9</td>
</tr>
<tr>
<td>$\mathbf{1}_{\text{His}}$</td>
<td>16</td>
<td>2.5&lt;sup&gt;b&lt;/sup&gt;</td>
<td>16.4 ± 0.3</td>
</tr>
<tr>
<td>$\mathbf{1}_{\text{His}}$</td>
<td>16</td>
<td>4.7&lt;sup&gt;a&lt;/sup&gt;</td>
<td>16.0 ± 0.3</td>
</tr>
<tr>
<td>$\mathbf{1}_{\text{His}}$</td>
<td>16</td>
<td>7.2&lt;sup&gt;c&lt;/sup&gt;</td>
<td>12.3 ± 1.2</td>
</tr>
</tbody>
</table>

<sup>a</sup>50 mM CD$_3$COOD and 50 mM CD$_3$COONa buffered D$_2$O.

<sup>b</sup>Unbuffered peptide in D$_2$O.

<sup>c</sup>50 mM CD$_3$COOD and 50 mM CD$_3$COONa buffered D$_2$O with the pH adjusted to 7.2 with NaOD.

NOESY NMR spectroscopy establishes that the structure of the tetramer formed by peptides $\mathbf{1}_{\text{Leu}}$ and $\mathbf{1}_{\text{Glu}}$ in aqueous solution is similar to the tetramer previously observed for peptide $\mathbf{1}_{\text{Cit}}$. The spectrum exhibits NOEs that correspond to the intramolecular contacts of the monomer, intermolecular contact of the dimer, and intermolecular contact of the tetramer. Three strong crosspeaks in the NOESY spectrum of peptides $\mathbf{1}_{\text{Leu}}$ indicate that the macrocyclic β-sheet monomers are well-folded, one between the α-protons of Leu$_{12}$ and Lys, one between the α-protons of Leu$_{16}$ and Lys, and one between the α-proton of Asn$_{14}$ and the proton at the 6-position of the tripeptide mimic Hao (Figure 4.8). In addition, a strong crosspeak between the α-protons of Ala$_{13}$ and Val$_{17}$ reflect a shifted, antiparallel dimer formation where the two heptapeptide β-strands are shifted by two residues towards the C-termini (Figure 4.7). A characteristic NOE between the methoxy group of Hao and the Ile side chain reflects packing of the dimers to form a sandwich like tetramer. The NOESY of peptide $\mathbf{1}_{\text{Glu}}$ exhibits the same NOE crosspeaks with the exception of one of the Leu-Lys crosspeaks that is buried due to overlap. These NOEs associated with the folded monomer, dimer, and tetramer indicate that peptides $\mathbf{1}_{\text{Leu}}$ and $\mathbf{1}_{\text{Glu}}$ form the same tetramer structure as peptide $\mathbf{1}_{\text{Cit}}$ in solution.
Figure 4.7. NOEs associated with the dimer subunit of peptide 1Glu and 1Leu (A) Expansion of the NOESY spectrum of peptide 1Glu showing selected intramolecular (blue) and intermolecular (red) NOE crosspeaks. (B) Expansion of the NOESY spectrum of peptide 1Leu showing selected intramolecular (blue) and intermolecular (red) NOE crosspeaks.
Inspired by these results and the role of pH in triggering changes in protein structure and interactions, I incorporated a histidine residue at position 11. I envisioned that peptide $\text{I}_{\text{His}}$ would change oligomerization state when triggered by the protonation of histidine ($\text{pK}_a \sim 6$). Below pH 6, it would form a monomer as the imidazole side chain is predominantly protonated, making it cationic like arginine. As the pH increases above 6, it would form a tetramer as the imidazole side chain loses a proton, making it neutral, like citrulline and leucine.

At pH 2.5, peptide $\text{I}_{\text{His}}$ is monomeric at 1 mM. The $^1\text{H}$ NMR spectrum of peptide $\text{I}_{\text{His}}$ exhibits a single set of sharp resonances, associated with the monomer (Figure 4.8). Similar to previous results, the resonances associated with the $\alpha$-protons are in the 4–5 ppm range, showing little to no downfield shifting relative to the typical values of the corresponding residues in a random coil conformation. The aromatic resonances of the Phe$_{15}$ side chains are at approximately 7 ppm, corresponding to typical random coil chemical shifts. The diffusion coefficient at 1 mM and pH 2.5 is $20.1 \times 10^{-7}$ cm$^2$/s, congruent with the diffusion coefficient of the monomeric peptide $\text{I}_{\text{Arg}}$. 

**Figure 4.8.** Shifted, antiparallel hydrogen-bonded dimer of peptide $\text{I}_{\text{Leu}}$. Blue arrows indicate intramolecular NOEs and red arrows indicate intermolecular NOEs observed in the NOESY spectrum. For peptide $\text{I}_{\text{Glu}}$, the Leu-Lys crosspeak cannot be observed due to overlap.
Figure 4.9. $^1$H NMR spectra of macrocyclic $\beta$-sheet peptides $1_{\text{His}}$. Spectra at pH 2.5 are in D$_2$O. Spectrum at pH 4.7 are in 50 mM CD$_3$COOD and 50 mM CD$_3$COONa buffer in D$_2$O at 298 K. Spectrum at pH 7.2 are in 50 mM CD$_3$COOD and 50 mM CD$_3$COONa buffer adjusted to pH 7.2 with NaOD in D$_2$O at 298 K. The red boxes highlight key resonances in the dimer.

At higher concentrations at pH 2.5, peptide $1_{\text{His}}$ forms a dimer—an oligomerization state that the Nowick group has not previously observed in Hao-containing macrocyclic $\beta$-sheet peptides. The $^1$H NMR resonances are somewhat broadened at 4 and 8 mM, but are sharp at 16 mM (Figure 4.9). The diffusion coefficients at 4 mM, 8 mM, and 16 mM are 16.8, 16.4, and $16.4 \times 10^{-7}$ cm$^2$/s respectively (Table 4.2). These values are 0.84–0.82 times that of the monomer, best matching a dimer and not matching a tetramer. The lack of change in diffusion coefficient from 8 mM to 16 mM indicates that the observed spectrum does not correspond to a rapid monomer-tetramer equilibrium, but instead represents a unique species — a dimer.

The spectrum of the dimer differs from that of the monomer and those of the other tetramers. The aromatic resonances of Phe$_{15}$ are shifted upfield by 0.2 ppm to 6.8 ppm, and the Hao$_4$ and Hao$_6$ resonances are shifted downfield by 0.2 ppm to 8.3 and 8.1 ppm respectively. The monomer subunit of the dimer folds better than the free monomer with the average difference in
chemical shifts of the diastereotopic pro-\(S\) and pro-\(R\) \(\delta\)-protons of the \(\delta\)-linked ornithine turn units increasing from 0.29 ppm at 1 mM to 0.47 ppm at 16 mM.

NOESY spectroscopy reveals relatively little about the structure of the dimer. The NOESY spectrum of peptide 1His at pH 2.5 and 16 mM shows negative NOEs, as would be expected for an oligomer but not a monomer. A crosspeak between the \(\alpha\)-protons of Leu and Lys and a crosspeak between the \(\alpha\)-proton of Asn\(_{14}\) and the proton at the 6-position of the Hao residue shows that the monomer subunit is folded into a \(\beta\)-sheet. No additional NOE crosspeaks between \(\alpha\)-protons are observed, which may reflect overlap of resonances or the lack of edge-to-edge contacts between the folded monomer subunits. NOE crosspeaks between the side chain of Phe\(_{15}\) and one of the isoleucine residues suggest hydrophobic packing, as do weaker NOE crosspeaks between the isoleucine side chain and the methoxy group of Hao.

Upon increasing the pH to pH 7.2, the \(^1\)H NMR spectrum changes dramatically. At pH 4.7 and 16 mM, the spectrum largely resembles that at pH 2.5, it is slightly broadened and the diffusion coefficient is \(16.0 \times 10^{-7}\) cm\(^2\)/s, suggesting the onset of further self association. At pH 7.2, the diffusion coefficient of peptide 1His at 16 mM is \(12.3 \times 10^{-7}\) cm\(^2\)/s, congruent with the formation of a tetramer. The \(^1\)H NMR spectrum is broad and new resonances appear in the \(\alpha\)-region and aromatic region, indicating the formation of a new species (Figure 4.9). The monomer subunits are fully folded with the average difference in chemical shifts of the diastereotopic pro-\(S\) and pro-\(R\) \(\delta\)-protons of the \(\delta\)-linked ornithine turn units at 0.67 ppm. The resonances associated with the \(\alpha\)-protons of the tetramer are shifted downfield of the HOD peak, reflecting the folding and assembly of the peptide. The aromatic resonances of the Phe\(_{15}\) side chains are shifted upfield to reflect packing of the aromatic side chains to form a hydrophobic core. The dimer resonances are no longer present at higher pH, showing a pH-dependent response.
The observation of a stable dimer of peptide 1His under acidic condition is interesting, because I do not observe dimer formation for peptides 1Cit, 1Glu, or 1Leu. In all conditions studied, I observe only monomer or tetramer for these peptides. The absence of observed dimer for these peptides does not mean that no dimer forms, but rather that under all conditions studied the monomer or tetramer predominates and that tetramer formation must be cooperative.

The formation of a dimer by peptide 1His under acidic conditions suggests that some feature or features of the protonated imidazole group stabilize the dimer, while destabilizing the tetramer. The extra charge of the protonated peptide 1His likely disrupts tetramer formation. The protonated imidazole group of peptide 1His is less hydrophilic than the guanidinium group of peptide 1Arg, which likely facilitates hydrophobic packing of the dimer. It is also interesting that the 1H NMR spectrum of 1Arg broadens slightly at 8 mM, indicating the onset of self association. It is likely that this hint of self association reflects the onset of dimerization, rather than tetramerization.

**Conclusion**

The NMR studies of macrocyclic β-sheet peptides 1Arg, 1Cit, 1Glu, 1Leu, and 1His show that modulation of charge can manipulate oligomerization state and variations in hydrophobicity can affect oligomerization propensity. These results demonstrate that an increase in positive charge on the hydrophobic surface led to an absence of tetramer formation and that an increase in hydrophobicity on the hydrophobic surface led to an increase in propensity to form tetramers. Installement of the histidine residue at position 11 provided a convenient pH trigger for modulating the overall charge of the hydrophobic surface, and NMR studies at various pH further corroborates that charge is important in oligomerization.
References


Material and Methods

Synthesis of Macrocyclic β-Sheet Peptides. Synthesis of the macrocyclic β-sheet peptides were performed as previously published. The peptides were purified by reverse-phase HPLC and the pure fractions were lyophilized to give 19 mg of peptide \(1\text{Glu}\), 22 mg of peptide \(1\text{Leu}\), and 8 mg of \(1\text{His}\). Based on resin loading, the yields are 7%, 9%, and 4%, respectively.

Macrocyclic β-Sheet peptide \(1\text{Glu}\): HRMS (ESI-TOF) \(m/z\): \([M + H]^+\) Calcd for C\(_{82}\)H\(_{134}\)N\(_{21}\)O\(_{20}\) 1733.0114; Found 1733.0093.

Macrocyclic β-Sheet peptide \(1\text{Leu}\): HRMS (ESI-TOF) \(m/z\): \([M + Na]^+\) Calcd for C\(_{83}\)H\(_{137}\)N\(_{21}\)O\(_{18}\)Na 1739.0348; Found 1739.0363.

Macrocyclic β-Sheet peptide \(1\text{His}\): HRMS (ESI-TOF) \(m/z\): \([M + H]^+\) Calcd for C\(_{83}\)H\(_{134}\)N\(_{23}\)O\(_{18}\) 1741.0277; Found 1741.0278.

NMR Spectroscopy of the Macrocyclic β-Sheet Peptides

Sample Preparation. NMR spectroscopy of the macrocyclic β-sheet peptides at pH 2.5 was performed in D\(_2\)O (D, 99.96%; Cambridge Isotope Laboratories, Inc.). NMR spectroscopy of the macrocyclic β-sheet peptides at pH 4.7 was performed in D\(_2\)O with 50 mM CD\(_3\)COOD (D, 99.5%; Cambridge Isotope Laboratories, Inc.) and 50 mM CD\(_3\)COONa (D, 99%; Cambridge Isotope Laboratories, Inc.). NMR spectroscopy of the macrocyclic β-sheet peptides at pH 7.2 was performed in D\(_2\)O with 50 mM CD\(_3\)COOD and 50 mM CD\(_3\)COONa with the pH adjusted using NaOD (D, 99.5%; Cambridge Isotope Laboratories, Inc.). The solutions were prepared by dissolving a weighed portion of the peptide in the appropriate volume of solvent. The molecular weights of the peptides were calculated as the TFA salts with all amino groups assumed to be protonated (\(1\text{Glu}\), M.W. 2188.87, \(1\text{Leu}\), M.W. 2172.93, and \(1\text{His}\), M.W. 2310.90). The solutions at
pH 4.7 and 7.2 contained 4,4-dimethyl-4-silapentane-1-ammonium trifluoroacetate (DSA) as an internal standard for referencing chemical shifts. The solutions were prepared and left for 24 h to allow complete hydrogen to deuterium exchange of the amide NH protons.

\(^1\text{H NMR, TOCSY, ROESY, and NOESY Data Collection.}\) NMR spectra were recorded on a Bruker 500 MHz spectrometer with a TCI cryoprobe. TOCSY spectra were recorded with 2048 points in the \(f_2\) dimension and 512 increments in the \(f_1\) dimension with a 150-ms spin-lock mixing time. TOCSY spectra were recorded with 2048 points in the \(f_2\) dimension and 512 increments in the \(f_1\) dimension with either a 100- or 150-ms spin-lock mixing time. NOESY spectra were recorded with 2048 points in the \(f_2\) dimension and 512 increments in the \(f_1\) dimension with a 150-ms mixing time.

\(^1\text{H NMR, TOCSY, and NOESY Data Processing.}\) NMR spectra were processed with BrukerXwinNMR software. Automatic baseline correction was applied in both dimensions after phasing the spectra. TOCSY spectra were Fourier transformed to a final matrix size of 4096 x 1024 real points using a Qsine weighting function and forward linear prediction. NOESY and ROESY spectra were Fourier transformed to a final matrix size of 4096 x 2048 real points using a Qsine weighting function and forward linear prediction.

\text{Diffusion-Ordered Spectroscopy (DOSY) Experiments.}\) DOSY experiments were performed on a Bruker 500 MHz spectrometer equipped with a TCI cryoprobe, with a diffusion delay (\(\Delta\)) of 75-ms and a diffusion gradient length (\(\delta\)) of 2.5-ms. Sixteen sets of FIDs were recorded with the gradient strength incremented from 5\%-95\% using a linear ramp. The combined FIDs were Fourier transformed in Bruker's TopSpin\textsuperscript{TM} software to give a pseudo-2D spectrum. After phasing and performing baseline correction, each pseudo-2D spectrum was processed with logarithmic scaling on the Y-axis. The Y-axis was calibrated to the diffusion
coefficient of the residual HOD peak in D₂O (1.9 x 10⁻⁹ m²/s at 298 K). The diffusion coefficients of the peptides were read and converted from logarithmic values to linear values.
References


RP-HPLC of Macrocyclic β-Sheet $1_{\text{Glu}}$

<table>
<thead>
<tr>
<th>Peak</th>
<th>RetTime</th>
<th>Type</th>
<th>Width</th>
<th>Area</th>
<th>Height</th>
<th>Area</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>#</td>
<td>[min]</td>
<td></td>
<td>[min]</td>
<td>[mAU s]</td>
<td>[mAU]</td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>8.861</td>
<td>MM</td>
<td>0.0677</td>
<td>1665.86951</td>
<td>410.1195</td>
<td>100.000</td>
<td></td>
</tr>
</tbody>
</table>

column: Aeris XB-C18 2.6μ
dimensions: 150 mm x 4.6 mm
mobile phase: A: H$_2$O, 0.1% TFA
B: CH$_3$CN, 0.1% TFA
gradient: A/B (95:5) to (0:100) in 20 min
flow rate: 1.0 mL/min
detection: VWD, wavelength = 214 nm
temperature: 298 K

MS (ESI) of Macrocyclic β-Sheet $1_{\text{Glu}}$

yitinw1_elanflv-khaoki-com-1 26 (0.477) Sm (SG, 2x3.00); Cm (16:49)

TOF MS ES+
1.28e4

calculated m/z for C$_{82}$H$_{133}$N$_{21}$O$_{20}$:

- [M+H]$^+$: 1733.01
- [M+2H]$^{2+}$: 867.01
- [M+3H]$^{3+}$: 578.34
\(^1\)H NMR of macrocyclic \(\beta\)-sheet peptide 1_{Leu}, 1 mM in 100 mM deuterioacetate buffer in D\(_2\)O at 500 MHz and 298 K
\(^1\text{H NMR of macrocyclic } \beta\text{-sheet peptide } \text{1Leu}, \text{ 1 mM in 100 mM deuterioacetate buffer in } D_2O \text{ at 500 MHz and 298 K} \)
$^1$H NMR of macrocyclic β-sheet peptide $^{1}$Leu, 1 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
\(^1\)H NMR of macrocyclic β-sheet peptide 1Leu, 1 mM in 100 mM deuterioacetate buffer in D\(_2\)O at 500 MHz and 298 K

![NMR spectrum](image_url)
$^1$H NMR of macrocyclic $\beta$-sheet peptide 1Leu, 1 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K

\[ \text{Diagram of macrocyclic peptide structure} \]
$^1$H NMR of macrocyclic $\beta$-sheet peptide $1_{\text{Leu}}$, 1 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
\(^1\)H NMR 2D TOCSY of macrocyclic \(\beta\)-sheet peptide \(1\text{Glu}\) with 150-ms spin-lock mixing time

1 mM in 100 mM deuterioacetate buffer in D\(_2\)O at 500 MHz and 298 K
$^1$H NMR 2D TOCSY of macrocyclic $\beta$-sheet peptide $1_{\text{Glu}}$ with 150-ms spin-lock mixing time

1 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR 2D ROESY of macrocyclic $\beta$-sheet peptide $^1$Glu with 150-ms spin-lock mixing time
1 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR 2D ROESY of macrocyclic $\beta$-sheet peptide $1_{\text{Glu}}$ with 150-ms spin-lock mixing time
1 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
\[ ^1H \text{NMR of macrocyclic } \beta\text{-sheet peptide } 1_{\text{Glu}}, 16 \text{ mM in } 100 \text{ mM deuterioacetate buffer in } D_2O \text{ at } 500 \text{ MHz and } 298 \text{ K} \]
\(^1\)H NMR of macrocyclic \(\beta\)-sheet peptide 1\textsubscript{Glu}, 16 mM in 100 mM deuterioacetate buffer in D\(_2\)O at 500 MHz and 298 K
$^1$H NMR of macrocyclic β-sheet peptide $1_{\text{Glu}}$, 16 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K

![NMR spectrum of macrocyclic peptide](image)
\[^1\text{H}\text{ NMR of macrocyclic }\beta\text{-sheet peptide }1_{\text{Glu}}, 16 \text{ mM in 100 mM deuterioacetate buffer in D}_2\text{O at 500 MHz and 298 K}\]

\[
\begin{align*}
\text{ppm} & \quad 4.2 & 4.4 & 4.6 & 4.8 & 5.0 & 5.2 & 5.4 & 5.6 \\
\text{Integral} & \quad 1.0000 & 2.0994 & 2.2359 & 2.0538 & 1.3986 & 1.4070 & 4.9983 & 4.5090 & 0.6771
\end{align*}
\]
$^1$H NMR of macrocyclic β-sheet peptide $1_{\text{Glu}}$, 16 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K

![NMR Spectrum]

---

Current Data Parameters
- USER: yilinw
- NAME: 20150414_YW_eLANFLV-IKhaoIK-16mM
- EXPNO: 1
- PROCNO: 1

F2 - Acquisition Parameters
- Date: 20150414
- Time: 21:58
- INSTRUM: cryo500
- PROBHD: 5 mm CPTCI 1H-
- PULPROG: zg30
- TD: 81728
- SOLVENT: D2O
- NS: 256
- DS: 2
- SWH: 8012.820 Hz
- FIDRES: 0.098043 Hz
- AQ: 5.0998774 sec
- RG: 5
- DW: 62.400 usec
- DE: 6.00 usec
- TE: 298.0 K
- D1: 0.10000000 sec
- MCREST: 0.00000000 sec
- MCWRK: 0.01500000 sec

F2 - Processing Parameters
- SI: 65536
- SF: 500.2200206 MHz
- WDW: EM
- SSB: 0
- LB: 0.30 Hz
- GB: 0
- PC: 4.00

1D NMR plot parameters
- CX: 22.80 cm
- CY: 45.00 cm
- F1P: 4.000 ppm
- F1: 2000.88 Hz
- F2P: 2.200 ppm
- F2: 1100.48 Hz
- PPMCM: 0.07895 ppm/cm
- HZCM: 39.49105 Hz/cm
$^1$H NMR of macrocyclic β-sheet peptide 1Glu, 16 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR 2D TOCSY of macrocyclic $\beta$-sheet peptide $\text{1Glu}$ with 150-ms spin-lock mixing time 16 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR 2D TOCSY of macrocyclic \( \beta \)-sheet peptide 1Glu with 150-ms spin-lock mixing time
16 mM in 100 mM deuterioacetate buffer in \( \text{D}_2\text{O} \) at 500 MHz and 298 K
$^1$H NMR 2D TOCSY of macrocyclic $\beta$-sheet peptide $1_{\text{Glu}}$ with 150-ms spin-lock mixing time
16 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR 2D TOCSY of macrocyclic $\beta$-sheet peptide $\text{1Glu}$ with 150-ms spin-lock mixing time
16 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR 2D NOESY of macrocyclic $\beta$-sheet peptide 1Glu with 150-ms mixing time
16 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR 2D NOESY of macrocyclic $\beta$-sheet peptide $1_{\text{Glu}}$ with 150-ms mixing time
16 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR 2D NOESY of macrocyclic $\beta$-sheet peptide $\text{1Glu}$ with 150-ms mixing time
16 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR 2D NOESY of macrocyclic β-sheet peptide 1Glu with 150-ms mixing time
16 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR DOSY of macrocyclic β-sheet peptide $\text{1Glu}$ at 500 MHz and 298 K
16 mM in 100 mM deuterioacetate buffer in D$_2$O

Calculation for macrocyclic β-sheet peptide $\text{1Glu}$ at 16 mM

$D_{\text{HOD}} = 19.0 \times 10^{-10}$ m$^2$/s

$\log(D_{\text{HOD}}) = -8.721$

$D_{\text{tetramer}} : \log(D) = -9.917; D = 10^{-9.917} = 12.1 \pm 0.6 \times 10^{-11}$ m$^2$/s

$^1$H NMR DOSY of macrocyclic $\beta$-sheet peptide $1_{\text{Glu}}$ at 500 MHz and 298 K
16 mM at pH 7.2 in D$_2$O

Calculations for macrocyclic $\beta$-sheet peptide $1_{\text{Glu}}$ at 16 mM and pH 7.2

$D_\text{HOD} = 19.0 \times 10^{-10}$ m$^2$/s $^a$

$\log (D_{\text{HOD}}) = -8.721$

$D_\text{tetramer} : \log(D) = -9.907; D = 10^{-9.907} = 12.4 \pm 0.3 \times 10^{-11}$ m$^2$/s

RP-HPLC of Macrocyclic β-Sheet 1Leu

<table>
<thead>
<tr>
<th>Peak</th>
<th>RetTime</th>
<th>Type</th>
<th>Width</th>
<th>Area</th>
<th>Height</th>
<th>Area</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>#</td>
<td>[min]</td>
<td></td>
<td>[min]</td>
<td>[mAU]°s</td>
<td>[mAU]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>------</td>
<td>---------</td>
<td>------</td>
<td>-------</td>
<td>--------</td>
<td>--------</td>
<td>------</td>
<td>----</td>
</tr>
<tr>
<td>1</td>
<td>10.274</td>
<td>MM</td>
<td>0.2254</td>
<td>8094.08105</td>
<td>598.6033</td>
<td>100.000</td>
<td></td>
</tr>
</tbody>
</table>

column: Aeris XB-C18 2.6μ
dimensions: 150 mm x 4.6 mm
mobile phase: A: H₂O, 0.1% TFA
B: CH₃CN, 0.1% TFA
gradient: A/B (95:5) to (0:100) in 20 min
flow rate: 1.0 mL/min
detection: VWD, wavelength = 214 nm
temperature: 298 K

MS (ESI) of Macrocyclic β-Sheet 1Leu

ylinw2-lanflv-ikhakoi-comb-1 26 (0.477) Sm (SG, 2x3.00): Cm (6:40)

calculated m/z for C₈₃H₁₃₇N₂₁O₁₈: 1717.05
[M+H]⁺: 1717.05
[M+2H]²⁺: 859.03
[M+3H]³⁺: 573.02

TOF MS ESI+
1.29e4
$^1$H NMR of macrocyclic $\beta$-sheet peptide 1Leu, 1 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
\(^{1}\)H NMR of macrocyclic \(\beta\)-sheet peptide 1_{Leu}, 1 mM in 100 mM deuterioacetic acid buffer in \(\text{D}_2\text{O}\) at 500 MHz and 298 K
1H NMR of macrocyclic β-sheet peptide 1_{Leu}, 1 mM in 100 mM deuterioacetate buffer in D_2O at 500 MHz and 298 K
$^1$H NMR of macrocyclic $\beta$-sheet peptide $1_{\text{Leu}},$ 1 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
\(^1\)H NMR of macrocyclic β-sheet peptide \(1_{\text{Leu}}\), 1 mM in 100 mM deuterioacetate buffer in D\(_2\)O at 500 MHz and 298 K
\( ^1H \) NMR of macrocyclic \( \beta \)-sheet peptide 1Leu, 1 mM in 100 mM deuterioacetate buffer in D\(_2\)O at 500 MHz and 298 K
$^1$H NMR 2D TOCSY of macrocyclic $\beta$-sheet peptide 1Leu with 150-ms spin-lock mixing time
1 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR 2D TOCSY of macrocyclic $\beta$-sheet peptide 1Leu with 150-ms spin-lock mixing time
1 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR 2D NOESY of macrocyclic $\beta$-sheet peptide 1Leu with 150-ms mixing time
1 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR 2D NOESY of macrocyclic β-sheet peptide 1Leu with 150-ms mixing time
1 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR of macrocyclic $\beta$-sheet peptide $\text{1Leu}$, 8 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
\[ {^1}H \text{ NMR of macrocyclic } \beta\text{-sheet peptide } 1_{\text{Leu}}, 8 \text{ mM in } 100 \text{ mM deuterioacetate buffer in } D_2O \text{ at } 500 \text{ MHz and } 298 \text{ K} \]
$^1$H NMR of macrocyclic β-sheet peptide $^{1}_{\text{Leu}}$, 8 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K

[Diagram of molecular structure]
$^1$H NMR of macrocyclic β-sheet peptide $1_{\text{Leu}}$, 8 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K.
$^1$H NMR of macrocyclic $\beta$-sheet peptide $1\text{Leu}$, 8 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR of macrocyclic β-sheet peptide 1_{Leu}, 8 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR 2D TOCSY of macrocyclic $\beta$-sheet peptide Leu with 150-ms spin-lock mixing time
8 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR 2D TOCSY of macrocyclic β-sheet peptide 1Leu with 150-ms spin-lock mixing time.
8 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K.
$^1$H NMR 2D TOCSY of macrocyclic $\beta$-sheet peptide $^{1}$Leu with 150-ms spin-lock mixing time
8 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^{1}H$ NMR 2D TOCSY of macrocyclic $\beta$-sheet peptide $1_{Leu}$ with 150-ms spin-lock mixing time
8 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR 2D NOESY of macrocyclic $\beta$-sheet peptide 1Leu with 150-ms mixing time
8 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR 2D NOESY of macrocyclic $\beta$-sheet peptide 1Leu with 150-ms mixing time
8 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR 2D NOESY of macrocyclic β-sheet peptide 1Leu with 150-ms mixing time
8 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^{1}$H NMR 2D NOESY of macrocyclic $\beta$-sheet peptide 1Leu with 150-ms mixing time
8 mM in 100 mM deuterioacetate buffer in D$_2$O at 500 MHz and 298 K
$^1$H NMR DOSY of macrocyclic β-sheet peptide $^{1}$Leu at 500 MHz and 298 K
16 mM in 100 mM deuterioacetate buffer in D$_2$O

Calculations for macrocyclic β-sheet peptide $^{1}$Leu at 16 mM and pH 4.7

$D_{HOD} = 19.0 \times 10^{-10}$ m$^2$/s
$log(D_{HOD}) = -8.721$

$D_{tetramer}: log(D) = -9.943; D = 10^{-9.943} = 11.4 \pm 0.5 \times 10^{-11}$ m$^2$/s

$^1$H NMR DOSY of macrocyclic $\beta$-sheet peptide 1Leu at 500 MHz and 298 K
16 mM at pH 7.2 in D$_2$O

Calculations for macrocyclic $\beta$-sheet peptide 1Leu at 16 mM and pH 7.2

$D_{\text{HOD}} = 19.0 \times 10^{-10}$ m$^2$/s $^a$

$\log(D_{\text{HOD}}) = -8.721$

$D_{\text{tetramer}} : \log(D) = -9.909; D = 10^{-9.909} = 12.3 \pm 1.3 \times 10^{-11}$ m$^2$/s

RP-HPLC of Macrocyclic β-Sheet 1\textsubscript{His}

![HPLC Chromatogram](image)

<table>
<thead>
<tr>
<th>Peak</th>
<th>RetTime</th>
<th>Type</th>
<th>Width</th>
<th>Area</th>
<th>Height</th>
<th>Area %</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>8.514</td>
<td>MM</td>
<td>0.1787</td>
<td>3.1333E4</td>
<td>2905.7468</td>
<td>100.000</td>
</tr>
</tbody>
</table>

**Column**: Aeris XB-C18 2.6μ
**Dimensions**: 150 mm x 4.6 mm
**Mobile phase**: A: H\textsubscript{2}O, 0.1% TFA
B: CH\textsubscript{3}CN, 0.1% TFA
**Gradient**: A/B (95:5) to (0:100) in 20 min
**Flow rate**: 1.0 mL/min
**Detection**: VWD, wavelength = 214 nm
**Temperature**: 298 K

**MS (ESI) of Macrocyclic β-Sheet 1\textsubscript{His}**

![MS Spectrum](image)

Calculated m/z for C\textsubscript{83}H\textsubscript{133}N\textsubscript{23}O\textsubscript{18}: 
- [M+H]\textsuperscript{+}: 1741.03
- [M+2H]\textsuperscript{2+}: 871.02
- [M+3H]\textsuperscript{3+}: 581.01

*Total Ion Chromatogram (TIC)*

**Calculated m/z (ESI)**
- [M+H]\textsuperscript{+}: 1741.91741.9
- [M+2H]\textsuperscript{2+}: 871.91740.9
- [M+3H]\textsuperscript{3+}: 581.91779.9
- [M+4H]\textsuperscript{4+}: 436.91739.9
- [M+5H]\textsuperscript{5+}: 362.91759.9
- [M+6H]\textsuperscript{6+}: 298.91779.9
- [M+7H]\textsuperscript{7+}: 234.91809.9
- [M+8H]\textsuperscript{8+}: 170.91839.9
- [M+9H]\textsuperscript{9+}: 106.91869.9
- [M+10H]\textsuperscript{10+}: 42.91899.9

\textcopyright 2023 by the American Chemical Society. All rights reserved.
$^1$H NMR of macrocyclic $\beta$-sheet peptide $\mathbf{1}_{\text{His}}$, 16 mM at pH 2.5 in D$_2$O at 500 MHz and 293 K
\(^1H\) NMR of macrocyclic \(\beta\)-sheet peptide \(1_{\text{His}}\), 16 mM at pH 2.5 in D\(_2\)O at 500 MHz and 293 K
$^1$H NMR of macrocyclic $\beta$-sheet peptide $1_{\text{His}}$, 16 mM at pH 2.5 in D$_2$O at 500 MHz and 293 K
\(^1\)H NMR of macrocyclic β-sheet peptide \(1_{\text{His}}\), 16 mM at pH 2.5 in D$_2$O at 500 MHz and 293 K
$^1$H NMR of macrocyclic $\beta$-sheet peptide $1_{\text{HIs}}$, 16 mM at pH 2.5 in D$_2$O at 500 MHz and 293 K
$^1$H NMR of macrocyclic $\beta$-sheet peptide $1_{\text{His}}$, 16 mM at pH 2.5 in D$_2$O at 500 MHz and 293 K

![1H NMR spectrum of macrocyclic $\beta$-sheet peptide $1_{\text{His}}$.]
$^1$H NMR 2D TOCSY of macrocyclic β-sheet peptide $^{1}$His with 150-ms spin-lock mixing time
16 mM at pH 2.5 in D$_2$O at 500 MHz and 293 K
$^1$H NMR 2D TOCSY of macrocyclic $\beta$-sheet peptide $1_{\text{His}}$ with 150-ms spin-lock mixing time
16 mM at pH 2.5 in D$_2$O at 500 MHz and 293 K
$^1$H NMR 2D NOESY of macrocyclic $\beta$-sheet peptide $1_{\text{HIS}}$ with 150-ms mixing time
16 mM at pH 2.5 in D$_2$O at 500 MHz and 293 K
\(^1\)H NMR 2D NOESY of macrocyclic \(\beta\)-sheet peptide 1His with 150-ms mixing time 16 mM at pH 2.5 in \(\text{D}_2\text{O}\) at 500 MHz and 293 K
$^1$H NMR DOSY of macrocyclic β-sheet peptide $^{1}{\text{His}}$ at 500 MHz and 298 K
1 mM at pH 2.5 in D$_2$O

Calculations for macrocyclic β-sheet peptide $^{1}{\text{His}}$ at 1 mM and pH 2.5

$D_{\text{HOD}} = 19.0 \times 10^{-10}$ m$^2$/s

$\log (D_{\text{HOD}}) = -8.721$

$D_{\text{monomer}} : \log(D) = -9.703; D = 10^{-9.703} = 19.8 \pm 0.8 \times 10^{-11}$ m$^2$/s

$^1$H NMR DOSY of macrocyclic $\beta$-sheet peptide 1His at 500 MHz and 298 K
4 mM at pH 2.5 in D$_2$O

Calculated for macrocyclic $\beta$-sheet peptide 1His at 4 mM and pH 2.5

$D_{\text{HOD}} = 19.0 \times 10^{-10}$ m$^2$/s

$\log (D_{\text{HOD}}) = -8.721$

$D_{\text{dimer}}: \log(D) = -9.775; D = 10^{-9.775} = 16.8 \pm 0.6 \times 10^{-11}$ m$^2$/s

\(^1\)H NMR DOSY of macrocyclic β-sheet peptide 1His at 500 MHz and 298 K
8 mM at pH 2.5 in D\(_2\)O

Calculations for macrocyclic β-sheet peptide 1His at 8 mM and pH 2.5

\[ D_{\text{HOD}} = 1.9 \times 10^{-10} \text{ m}^2/\text{s} \]
\[ \log(D_{\text{HOD}}) = -8.721 \]
\[ D_{\text{dimer}} : \log(D) = -9.785; D = 10^{-9.785} = 16.4 \pm 0.9 \times 10^{-11} \text{ m}^2/\text{s} \]

$^1$H NMR DOSY of macrocyclic $\beta$-sheet peptide 1His at 500 MHz and 298 K
16 mM at pH 2.5 in D$_2$O

Calculations for macrocyclic $\beta$-sheet peptide 1His at 16 mM and pH 2.5

$D_{\text{HOD}} = 19.0 \times 10^{-10}$ m$^2$/s $^a$

$\log (D_{\text{HOD}}) = -8.721$

$D_{\text{dimer}} : \log(D) = -9.785; D = 10^{-9.785} = 16.4 \pm 0.3 \times 10^{-11}$ m$^2$/s

$^1$H NMR DOSY of macrocyclic $\beta$-sheet peptide $1_{\text{His}}$ at 500 MHz and 298 K
16 mM at pH 4.7 in D$_2$O

Calculations for macrocyclic $\beta$-sheet peptide $1_{\text{His}}$ at 16 mM and pH 4.7

$D_{\text{HOD}} = 19.0 \times 10^{-10}$ m$^2$/s $^a$

$\log (D_{\text{HOD}}) = -8.721$

$D_{\text{dimer}} : \log(D) = -9.785; D = 10^{-9.785} = 16.4 \pm 0.3 \times 10^{-11}$ m$^2$/s

$^1$H NMR of macrocyclic $\beta$-sheet peptide $1_{\text{His}}$, 16 mM at pH 7.2 in D$_2$O at 500 MHz and 293 K
\( ^1 \text{H NMR of macrocyclic \( \beta \)-sheet peptide 1His, 16 mM at pH 7.2 in D}_2\text{O at 500 MHz and 293 K} \)
$^1$H NMR of macrocyclic β-sheet peptide $^1$His, 16 mM at pH 7.2 in D$_2$O at 500 MHz and 293 K.
$^1$H NMR of macrocyclic β-sheet peptide $1_{\text{His}}$, 16 mM at pH 7.2 in D$_2$O at 500 MHz and 293 K
$^1$H NMR of macrocyclic $\beta$-sheet peptide $1_{\text{His}}$, 16 mM at pH 7.2 in D$_2$O at 500 MHz and 293 K
$^1$H NMR 2D TOCSY of macrocyclic $\beta$-sheet peptide $1_{\text{His}}$ with 150-ms spin-lock mixing time
16 mM at pH 7.2 in $D_2O$ at 500 MHz and 298 K
$^1$H NMR 2D TOCSY of macrocyclic $\beta$-sheet peptide $^{1}$His with 150-ms spin-lock mixing time
16 mM at pH 7.2 in D$_2$O at 500 MHz and 298 K
$^1$H NMR 2D NOESY of macrocyclic $\beta$-sheet peptide $^1$His with 150-ms mixing time
16 mM at pH 7.2 in D$_2$O at 500 MHz and 298 K
$^1$H NMR 2D NOESY of macrocyclic β-sheet peptide $^1$His with 150-ms mixing time
16 mM at pH 7.2 in D$_2$O at 500 MHz and 298 K
$\text{H NMR DOSY of macrocyclic } \beta\text{-sheet peptide 1His at 500 MHz and 298 K} $

16 mM at pH 7.2 in D$_2$O

Calculations for macrocyclic $\beta$-sheet peptide 1His at 16 mM and pH 7.2

$D_{\text{HOD}} = 19.0 \times 10^{-10}$ m$^2$/s $^a$

$\log (D_{\text{HOD}}) = -8.721$

$D_{\text{tetramer}} : \log(D) = -9.910; D = 10^{-9.910} = 12.3 \pm 1.2 \times 10^{-11}$ m$^2$/s

Chapter 5

My Teaching Experiences
My transition from the Nowick lab to an instructor position was motivated by my desire to teach. I am excited at the prospect of engaging a diverse group of students in stimulating chemistry learning material, collaborating with colleagues, developing new effective curriculum, and improving and assessing student learning outcomes. I have always been excited about chemistry and I bring that energy into the classroom, encouraging students to discuss chemistry problems with each other as a dynamic way to develop their communication skills. As a recent Pedagogical Fellow (PF) undergoing advanced pedagogy training, I am eager to apply what I have learned to mentor my future students.

In the summer of 2016, I had the opportunity to instruct 30 students in an undergraduate course Chem 128, “Introduction to Chemical Biology.” This position has given me valuable experience in lecturing and preparing course material. As a student, I always found that staying engaged is paramount to a better learning experience. Research shows that by incorporating active learning methods such as demonstration and questions, students reported fewer attention lapses.\textsuperscript{1,2} To this end, I incorporated active learning techniques such as a modified \textit{semi-flipped classroom} approach in my lectures.\textsuperscript{2} Each class was set up such that a portion of the class was dedicated to lecturing and short 5-10 minute segments were set aside for students to tackle problems relevant to material covered. I adopted this approach as way for student self-assessment, so students have a chance to learn a concept and apply it to problem solving. This modified \textit{semi-flipped classroom} approach helps students identify their knowledge gaps. During the lecture, I used formative assessment to track student learning and adjust the pacing of the class accordingly. Student evaluations showed that they liked the example problems as it helped them assess where they stood and what they needed to improve. My experience taught me that teaching is more than just communicating knowledge. Teaching, to me, is about inspiring
students to develop interest in the subject, which will in turn empower them to take ownership of their learning. In instructing Chem 128, I had the opportunity to teach a small group of students in an intimate setting.

Due to positive student evaluations from Chem 128, I was nominated to instruct an organic chemistry course with 370 students in the spring of 2017. I viewed this opportunity as a chance to incorporate and experiment with different teaching methods. One of the challenges of teaching such a big class is the perceived anonymity of the students, which can lead to lower class participation and student involvement.³,⁴ This class also poses an added challenge of being an 8 AM class, which increases absenteeism and tardiness.⁵,⁶ I discussed this with other PFs in my pedagogical program and tried to come up with various fun active learning activities that will work in a large lecture course and stimulate discussion amongst the students. For example, think-pair-share (TPS) is a collaborative learning strategy that can work with a class of any size. Students participate in TPS by (1) thinking individually about a topic or a question; and (2) sharing their ideas with classmates or the entire class. It is a great way for students to develop essential oral communication skills and build a learning community. Think-pair-share is also an efficient icebreaker for shy and quieter students to start speaking in class.

To complement the think-pair-share activities, I incorporated iClickers, a student response system that allows me to gauge student learning in the form of multiple-choice questions.¹⁷⁻⁹ The questions are shown on the projector slide and the polling results are shown as bar graphs. The low-stake iClicker problems are purposefully spaced 10 to 15 minutes apart to refresh a student's attention span. Research shows that low-stake assignments effectively provide students with a realistic idea of their performance early on in the course and increase students' willingness to seek help.¹⁰ When encountering iClicker problems where students are divided in
their solutions, I adopt TPS and have students discuss the question with their partners. The activity identifies misconceptions and gives every student a voice. Student evaluations showed that students found the iClicker problems useful in helping them understand the lecture material. In teaching this course, I learned the importance of incorporating effective active learning activities to increase motivation, engagement and community building.

Throughout my graduate career, I was a teaching assistant for over 10 chemistry lecture and laboratory courses. Similar to my experiences as an instructor, I strived to engage my students and have them engage with the material. In Spring 2013, I implemented collaborative learning activities in my organic chemistry discussion sections to foster an inclusive learning environment and increase student participation. I structured the discussion section such that the students began by working on a worksheet individually for a short period of time, 10-15 minutes, before they were divided into smaller groups of four or five students. The groups then had 25-30 minutes to discuss the worksheet before a student is selected at random to present a problem to the class. During this gap, I actively walked around the classroom to answer questions and address misconceptions. With small teams and a clear goal, I found that all students actively participated and even the shy, quieter students are not afraid to present problems to the class. This fostered a friendly and welcoming atmosphere, which further encouraged participation. I first learned about this technique through Professor David Van Vraken at UCI, who used it in his graduate course that I was enrolled in. In his course, the collaborative learning activities made students feel comfortable and included. I learned by example and direct experience that an inclusive environment will encourage students to interact with one another and even form study groups outside of class, building a strong sense of community.
In addition to active learning activities, I am also interested in incorporating technology in my classrooms. I have experience in using course management systems such as Canvas, which allows students to effectively navigate through course material and announcements. Another useful online tool I have experience with is Piazza, which is an online gathering space for students to ask questions and answer questions posted by other students. I look forward to learning about more technology tools in my pedagogy training.

Diversity arises from a wide range of experiences, backgrounds, and interests. In teaching a physical science subject such as Chemistry, socioeconomic status and language differences are diversity that needs to be addressed in the classroom. Unlike the social sciences subjects, topics of ethnicity, race, gender, sexual orientation, and religion are less likely to arise. Therefore, it is important to be compassionate and understanding when teaching. When teaching Chem 128, one of the students was unable to attend the final exam as she had recently been a victim of domestic abuse. It was an incredibly stressful time for her and I worked closely with the Campus Assault Resources and Education (CARE) counselors to minimize her trauma. We were able to schedule her exam at a much later time so that she is not disadvantaged because of her situation. If a student is performing adequately in class, I believe that it is important that the instructor is accommodating towards extenuating circumstances. With UCI being a minority-majority campus, half of my Chem 128 class was ESL and international students. When they were working on their final project of summarizing a research article, many struggled with comprehension. As I started learning English when I was six-years-old, I could relate to them and was able to offer useful advice on how to read a scientific article. As an instructor, I strive to maximize my students’ learning potential by being empathetic and understanding.
As a recent PF, I have had the pleasure of working with like-minded individuals in the Pedagogical Fellows Program. The program provides an interdisciplinary community that provides professional and personal support. In one of the mandatory classes, University Studies 390A, PFs had the opportunity to discuss current and prominent literature in active learning, course design, inclusive teaching, assessment, instructional technology, and collaborative learning. The discussions were especially fruitful as PFs from different disciplines often had extremely different perspectives of the readings.

In conclusion, I am dedicated to providing a learning environment that is both engaging and supportive, one that empowers student learning. I implemented different active learning activities based on class sizes and assessed student learning outcomes by both formative and summative assessment. In the future, I hope to gain more experience as an instructor by teaching preparatory chemistry and general chemistry courses.

References